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ABSTRACT
These guidelines update previous guidance published in
2005. They have been revised by a group who are
members of the UK and Ireland Neuroendocrine Tumour
Society with endorsement from the clinical committees
of the British Society of Gastroenterology, the Society for
Endocrinology, the Association of Surgeons of Great
Britain and Ireland (and its Surgical Specialty
Associations), the British Society of Gastrointestinal and
Abdominal Radiology and others. The authorship
represents leaders of the various groups in the UK and
Ireland Neuroendocrine Tumour Society, but a large
amount of work has been carried out by other
specialists, many of whom attended a guidelines
conference in May 2009. We have attempted to
represent this work in the acknowledgements section.
Over the past few years, there have been advances in
the management of neuroendocrine tumours, which have
included clearer characterisation, more speciﬁc and
therapeutically relevant diagnosis, and improved
treatments. However, there remain few randomised
trials in the ﬁeld and the disease is uncommon, hence all
evidence must be considered weak in comparison with
other more common cancers.
RECOMMENDATIONS
General recommendations
< Multidisciplinary teams (MDTs) at referral
centres should give guidance on the deﬁnitive
management of patients with all varieties of
neuroendocrine tumours (NETs). Level of
evidence 5, Grade of recommendation D.
< MDT representation should normally include
specialist physicians in NETs (gastroenterologists,
oncologists and/or endocrinologists), surgeons,
radiologists, nuclear medicine specialists, histo-
pathologists and clinical nurse specialists. Level of
evidence 5, Grade of recommendation D.
Genetics
< Clinical examination to exclude complex cancer
syndromes (eg, multiple endocrine neoplasia 1
(MEN1)) should be performed in all cases of
NETs, and a family history taken. Level of
evidence 4, Grade of recommendation C.
< In all cases where there is a family history of
NETs, or a second endocrine tumour, a familial
syndrome should be suspected. Level of evidence
4, Grade of recommendation C.
< In all patients, secondary tumours and other gut
cancers should be considered. Level of evidence 4,
Grade of recommendation C.
Diagnosis (biochemical measurements)
If a patient presents with symptoms suspicious of
a gastroenteropancreatic NET:
< Baseline tests should include plasma chromog-
ranin A and urinary 5-hydroxyindoleacetic acid.
Level of evidence 3, Grade of recommendation C.
< Speciﬁc biochemical tests should be requested
depending on which syndrome is suspected.
Level of evidence 3, Grade of recommendation C.
Imaging
< For detecting the primary tumour a multi-
modality approach is best. CT, MRI and
somatostatin receptor scintigraphy (SSRS) are
recommended. Gallium-68 (
68Ga) positron emis-
sion tomography (PET)/CT is recommended for
the detection of an unknown primary. Level of
evidence 3, Grade of recommendation A/B.
< Additional imaging modalities may include
endoscopic ultrasound (EUS), endoscopy,
digital subtraction angiography (DSA) and
venous sampling. Level of evidence 4, Grade of
recommendation B/C.
< For assessing secondaries,
68Ga PET/CT is the
most sensitive modality. Where this is not
available, SSRS in combination with CT is the
most sensitive modality. Level of evidence 3,
Grade of recommendation B.
< Histopathology is required to conﬁrm the
diagnosis. Level of evidence 3, Grade of recom-
mendation B.
< When a primary has been resected, cross-
sectional imaging (CT and MRI) using RECIST
criteria and SSRS may be indicated for follow-
up
1 if the patient is involved in a clinical trial.
Level of evidence 5, Grade of recommendation D.
Pathology
< Pathology is currently the diagnostic gold
standard. Level of evidence 5, Grade of recom-
mendation D.
< Pathology reporting and reviews should be made
by the MDT pathologist. Level of evidence 5,
Grade of recommendation D.
< Additional appendices are
published online only. To view
these ﬁles, please visit the
journal online (http://gut.bmj.
com).
For numbered afﬁliations see
end of article.
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Guidelines< Pathological characterisation and classiﬁcation of NETs
should be based on the WHO 2010 classiﬁcation, the Union
for International Cancer Control (UICC) TNM (7th edition),
and the European Neuroendocrine Tumour Society (ENETS)
site-speciﬁc T-staging system. Level of evidence 5, Grade of
recommendation D.
Therapy
< The aim of treatment should be curative where possible.
< The main aim is to keep the patient disease and symptom-
free for as long as possible and to maintain a good quality of
life (QoL).
< The extent of the tumour, its metastases, histological grade
and secretory proﬁle should be determined as far as possible
before planning treatment. Level of evidence 4, Grade of
recommendation C.
< The choice of treatment depends on the symptoms, stage of
disease, degree of uptake of radionuclide and the histological
features of the tumour. Level of evidence 4, Grade of
recommendation C.
< Surgery should be offered when NETs are resectable and there is
curative intent (or when debulking offers palliation) to patients
who are ﬁt and have limited diseasedprimary 6 regional
lymph nodes. Level of evidence 4, Grade of recommendation C.
< Surgery should be considered in those with liver metastases
and potentially resectable disease. Level of evidence 4, Grade
of recommendation D.
< For patients who are not ﬁt for surgery, the aim of treatment
is to improve symptoms and maintain an optimal QoL, and
where possible to improve survival. Level of evidence 5, Grade
of recommendation D.
< Treatment choices for non-resectable disease include somato-
statin analogues, biotherapy, targeted radionuclide therapy,
locoregional treatments including ablation and (chemo)
embolisation and chemotherapy. Level of evidence 4, Grade
of recommendation C.
< External beam radiotherapy may relieve bone pain from
metastases. Level of evidence 4, Grade of recommendation C.
< Chemotherapy may be used for inoperable or metastatic
pancreatic NETs. Level of evidence 1, Grade of recommenda-
tion A.
< Chemotherapy may be used for poorly differentiated NETs and
in selected non-pancreatic NETs of high grade or aggressive
clinical course. Level of evidence 2, Grade of recommendation B.
< Sunitinib or everolimus may be used as a line of therapy for
patients with advanced (inoperable or metastatic), progres-
sive (radiological evidence of disease progression within
12 months), well-differentiated pancreatic NETs. Level of
evidence 1, Grade of recommendation A.
< If possible, patients with NETs should be entered into formal
trials of new drug treatments. Level of evidence 4, Grade of
recommendation C.
Ablation
< In the setting of metastatic NET, ablation most commonly
has a role in small volume tumours, paucilesional disease or in
combination with resection. Level of evidence 3, Grade of
recommendation C.
< Ablation, in common with resection, has been shown to be
useful in symptom relief. Level of evidence 3, Grade of
recommendation C.
< Image-guided ablation can contribute to the cytoreductive
approach to metastatic disease. Level of evidence 3, Grade of
recommendation C.
Carcinoid heart disease (CHD)
< All patients with midgut NETs, with or without hepatic
metastasis, and all patients with the carcinoid syndrome,
should be screened for CHD: this may include N-terminal
pro-brain natriuretic peptide (NT-proBNP) and echocardiog-
raphy. Level of evidence 1b, Grade of recommendation B.
< Patients with elevated NT-proBNP (>260 pg/ml (>30 pmol/
l) based on single institution data) should be screened with
echocardiography. Level of evidence 1b, Grade of recommen-
dation B.
< Referral of patients with conﬁrmed CHD to a cardiology
department with expertise in dealing with CHD should be
considered. Level of evidence 5, Grade of recommendation D.
< Cardiac surgery should be considered in appropriate cases and
should be performed by skilled operators in selected centres
with experience of dealing with patients with NET. Level of
evidence 2c, Grade of recommendation C.
ORIGIN AND PURPOSE OF THESE GUIDELINES
These guidelines update previous guidance published in 2005.
2
They have been revised by a group who are members of the UK
and Ireland Neuroendocrine Tumour Society (UKINETS), with
endorsement from the clinical committees of the British Society
of Gastroenterology, the Society for Endocrinology, the Associ-
ation of Surgeons of Great Britain and Ireland (and its Surgical
Specialty Associations), the British Society of Gastrointestinal
and Abdominal Radiology, and others. The authorship repre-
sents leaders of the various groups within UKINETS, but a large
amount of work has been carried out by other specialists, many
of whom attended a guidelines conference in May 2009. We have
attempted to represent this work in the acknowledgements
section. Over the past few years, there have been advances in the
management of NETs, which have included clearer character-
isation, more speciﬁc and therapeutically relevant diagnosis, and
improved treatments. However, there remain few randomised
trials in the ﬁeld and the disease is uncommon, hence all
evidence must be considered weak in comparison with other
more common cancers.
It is the unanimous view of the guideline authors that MDTs
at referral centres should give guidance on the deﬁnitive
management of patients with all varieties of NETs, with
a particular emphasis on gastroenteric and pancreatic NETs, but
also including pulmonary NETs. MDT representation should
normally include physicians (gastroenterologists, oncologists
and/or endocrinologists), surgeons, radiologists, nuclear medi-
cine specialists, histopathologists and clinical nurse specialists.
The working party that produced these updated guidelines
included specialists from these various disciplines who
contribute to the management of all NETs, including gastroin-
testinal NETs. The purpose of these guidelines is to identify and
inform the key decisions to be made in the management of
gastroenteropancreatic NETs.
The guidelines are not intended to be a rigid protocol, but
form a basis upon which to aim for improved standards in the
quality of treatment given to affected patients.
The terminology used in this guideline has been chosen to
reﬂect the more modern use of the term ‘NET’ rather than the
older but often more familiar term ‘carcinoid tumour’.T h i s
decision reﬂects both the aetiology of NETs and that these
tumours are found in diverse locations, not just in the gastro-
intestinal tract. The term ‘carcinoid tumour’ is still commonly
used in clinical practice, but is deemed obsolete by many
experts. However, we retain the terms ‘carcinoid syndrome’
Gut 2012;61:6e32. doi:10.1136/gutjnl-2011-300831 7
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introduced.
FORMULATION OF THE GUIDELINES
Literature search
Members of the guidelines working party were assigned sections
of the 2005 guidance to update. A systematic review of the
relevant literature was performed, with synthesis of the avail-
able evidence; this was followed by peer group appraisal and
then expert review.
Categories of evidence
The Oxford Centre for Evidence-based Medicine’s Levels of
Evidence (May 2001) were used to evaluate the evidence cited in
these guidelines.
3
AETIOLOGY, EPIDEMIOLOGY, CLINICAL FEATURES, PROGNOSIS
AND GENETICS
Aetiology
The aetiology of NETs is poorly understood. Most NETs are
sporadic but there is a small familial risk (see under Genetics).
NETs constitute a heterogeneous group of neoplasms that share
certain characteristic biological features, and can therefore be
considered a common entity. The origin of the cells in the gut is
debated, but they may arise from pluripotential progenitor cells
that develop neuroendocrine characteristics. It seems unlikely
that these cells migrate in from the neural crest, as previously
thought. Such tumours originate from pancreatic islet cells,
gastroenteric tissue (from diffuse neuroendocrine cells distrib-
uted throughout the gut), neuroendocrine cells within the
respiratory epithelium, and parafollicullar cells distributed
within the thyroid (these tumours being referred to as medullary
carcinomas of the thyroid). Pituitary, parathyroid and adreno-
medullary neoplasms share certain characteristics with these
tumours, but are not considered here. These guidelines apply to
all NETs arising from the gut, including the pancreas and liver
(gastroenteropancreatic), as well as those arising from the lung
that have metastasised to the liver or abdominal lymph nodes.
Small intestinal and pancreatic NETs have different signatures,
as do benign and malignant tumours. The general term of
NET is preferred and encouraged for describing gastrointestinal
and pancreatic NETs (often denoted pNET), although the
term carcinoid is still in common usage and usually denotes
a well-differentiated serotonin (5-hydroxytryptamine)-secreting
midgut tumour.
Historically, gut-derived NETs were classiﬁed according to
their embryological origin, into tumours of the foregut (bronchi,
stomach, pancreas, gallbladder, duodenum), midgut (jejunum,
ileum, appendix, right colon) and hindgut (left colon, rectum).
4
The WHO has issued guidance on the classiﬁcation of NETs
according to histopathological characteristics (see under
Pathology). The molecular biology of NETs is still poorly
understood but there are emerging data to suggest that molec-
ular proﬁling and identiﬁcation of common genetic elements
may enhance tumour classiﬁcation and identify potential targets
that may be involved in tumour progression.
5e7
Epidemiology
The incidence of NETs is reported to be rising. Early data from
the UK, Sweden and Switzerland
8e11 suggested that the inci-
dence of gastrointestinal NETs was between 2 and 3 per 100000
persons per year with an overall slight preponderance in women.
The largest and most recent analyses of the epidemiology of
NETs have examined data from the USA (the Surveillance,
Epidemiology and End Results (SEER) Programme) and Norway
(the Norwegian Registry of Cancer (NRC)).
12e14 The USA data
cover nearly ﬁve decades and demonstrate a steady increase in
the incidence, or reporting, of stomach and rectal tumours and
a decrease in that of appendiceal NETs.
12 14 There are reported
ethnic differences in NET incidence, with AfricaneAmericans
having the highest overall value at 6.5 per 100000 per year.
12
The most common site for a primary NET in Caucasians in the
USA is the lung, accounting for about 30% of all new
cases, whereas in Asian/Paciﬁc, American Indian and
AfricaneAmericans the rectum is the most common site, with
about 27% of new cases having the primary here.
12 In Norway,
the most common primary site is the small intestine (25%).
13
The overall incidence of NETs in Caucasians is 4.44 per 100000
persons per year in the USA and 3.24 per 100000 persons per
year in Norway. This rate of occurrence is higher than previously
thought, but is in keeping with data from autopsy studies in
Sweden from 30 years ago.
15
Other analyses suggest an even higher incidence of NETs,
reporting a fourfold increase between 1973 and 2004, from 2.1 to
9.3 new cases per 100000 persons per year.
16 This report
concluded that NETs are the most common small bowel tumour
(37.4%), followed by adenocarcinoma (36.9%), lymphomas
(17.3%) and stromal tumours (8.4%). However, another analysis
of the SEER dataset from the USA suggests that the rate of
increase in the incidence of NETs has been from 1.09 to 5.25 per
100000 persons per year over the same time period.
14 The
incidence of tumours in the appendix, caecum and pancreas
almost doubled between 1975 and 2005, but collectively these
tumours make up only a small percentage of the total number of
cases, and for each the incidence is about 0.1e0.2 per 100000
persons per year. The incidence of rectal, small intestinal and
pulmonary primaries increased by 4e5-fold over the same period
with incidences of between 0.9 and 1.3 per 100000 persons per
year.
12 14 17
Whatever the precise incidence of NETs, it appears that the
number of patients presenting with these tumours has been
steadily increasing.
18 Indeed, since many NETs are slow-growing
or of uncertain malignant potential, with even malignant NETs
associated with prolonged survival, the prevalence of NETs is
relatively high.
14 It is reported that, despite the rising number of
cases, there is still a delay of up to 7 years between the
appearance of ﬁrst symptoms and a diagnosis of NET.
18
It is not possible to predict who might develop a NET. There is
an increased risk in patients with atrophic gastritis and persons
of Afro-Caribbean origin.
19 In the USA, there is evidence that
a long-term history of diabetes mellitus, especially when
combined with a family history of cancer, also increases the risk
of developing a gastric NET.
20 This work also reported that
a history of smoking or alcohol use has no apparent effect on the
risk of developing a NET. Overall, men have a greater risk than
women of developing small bowel cancer, and small intestinal
NETs are 30% more common in men than in women.
13
The sites and overall frequencies of primary NETs, as reported
in the USA and Norway, are shown in table 1.
13 A number of
other national databases are in the process of reporting and
publication, although most suffer from selective reporting and
accrual from specialist centres. In general, however, the rates
and tumour types in table 1 are in agreement with these series.
The frequencies of primary NETs reported as occurring in
the liver or biliary tract were <1%. Unknown primary sites or
sites other than those listed in table 1 accounted for 11e14%
of cases.
13
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GuidelinesFor patients with a small bowel primary NET, the likelihood
of nodal metastases being present at the time of diagnosis is
about 60%, irrespective of the precise site of origin within the
small bowel; with a colonic primary, the likelihood is about
40e70%, with a greater risk within this range if the primary is in
the ascending colon, and a lower risk if the primary is in the
rectum.
12 Nodal metastases are present in 5% of patients with
an appendiceal primary and 15% of those with a pulmonary
primary.
12 The chance of liver metastases being present at the
time of diagnosis is about half the risk of nodal spread having
occurred.
12
The chance of metastases being present at the time of
diagnosis and the likelihood of MEN1 is shown in table 2.
Clinical features
Gastroenteropancreatic NETs may be classiﬁed into non-func-
tioning tumours, which have no hormone-related clinical
features, and functioning tumours, which cause symptoms due
to peptide and hormone release. In all NETs, presenting features
may include non-speciﬁc symptoms such as pain (which may be
intermittent and present for many years), nausea and vomiting,
and, in some cases, anaemia due to intestinal blood loss
(table 3).
18 25e27 Pain may be due to local tumour invasion,
bowel obstruction or mesenteric ischaemia. Most gastro-
enteropancreatic NETs are non-functioning and present with
mass effects of the primary tumour or metastases (usually liver).
A high index of suspicion is needed to identify patients, and
diagnosis is often delayed for several years, often made as
an incidental ﬁnding at surgery or during radiological
assessment.
28e32 Gastroenteropancreatic NETs are also associ-
ated with other primary malignancies.
Non-functioning gastroenteropancreatic NETs
Gastric and rectal NETs are often diagnosed coincidentally at
endoscopy, or may be the source of anaemia. Type I and II gastric
NETs are related to hypergastrinaemia, and are usually small
(measuring several millimetres) and multiple. Type I tumours are
associated with achlorhydria, while type II are associated with
ZollingereEllison syndrome and MEN1; neither are likely to
metastasise when small. In contrast, type III gastric NETs are
often larger (measuring several centimetres) and solitary, are not
associated with elevated gastrin, and usually have malignant
potential. Appendiceal NETs may be identiﬁed during surgery for
appendicitis, or during colonic surgery, and are less commonly
associated with a secretory syndrome. Approximately 60% of all
pancreatic NETs are non-functioning. The primary tumour may
be large at presentation, when approximately 50% have meta-
stasised. UK data show that bronchial NETs may present with
cough and recurrent pneumonia (22%), incidentally on chest
radiography (18%), with haemoptysis (13%), or with shortness
of breath (9%).
33 Rarely, these tumours may be associated with
ectopic adrenocorticotropic hormone (ACTH) secretion and
Cushing’s syndrome.
Functioning tumours
Functioning pancreatic NETs cause symptoms dependent on the
peptide hormone released (table 3).
Carcinoid syndrome
Carcinoid syndrome occurs in w20% of cases of well-differentiated
endocrine tumours of the jejunum or ileum (midgut NET) and
consists of (usually) dry ﬂushing (without sweating; 70% of
cases
34) with or without palpitations, diarrhoea (50% of cases) and
intermittent abdominal pain (40% of cases)
35; in some patients,
there is also lacrimation and rhinorrhoea. Carcinoid syndrome
occurs less often with NETs of other origins and is very rare in
association with rectal NETs. It is usually due to metastasis to the
liver, with the release of vasoactive compounds, including biogenic
amines (eg, serotonin and tachykinins), into the systemic circula-
tion. However, it may also occur in the absence of liver metastases
if there is direct retroperitoneal involvement, with venous drainage
bypassing the liver. Pain due to hepatic enlargement may also be
a presenting feature, as may upper right abdominal pain (similar
to that of pulmonary infarction) secondary to either haemor-
rhage into, or necrosis of, a hepatic secondary tumour. Wheezing
and pellagra are less common presenting features. CHD is
present in w20% of patients at presentation and usually
Table 1 Sites and overall frequencies of primary NETs in the USA
(from the SEER Programme) and Norway (from the NRC)
12e14
Primary NET
Percentage of cases
SEER (n[17321)
Black patients White patients NRC (n[2013)
Lung 18.3 31.9 21.0
Stomach 5.7 5.7 5.7
Small intestine 21.0 17.7 25.5
Pancreas 3.7 4.1 6.9
Meckel 0.1 0.4 0.5
Appendix 2.0 3.2 4.8
Colon 7.9 7.4 8.0
Rectum 27.0 12.3 7.2
Breast 0.4 0.4 1.6
Prostate 0.3 0.4 1.5
Ovary 1.2 1.6 2.4
NET, neuroendocrine tumour; NRC, Norwegian Registry of Cancer; SEER, Surveillance,
Epidemiology and End Results.
Table 2 Location, likelihood of metastasis and association with MEN1
in NETs
21 22
Tumour % Metastases % MEN1
Incidence per
million per year
Insulinoma 10 5 1e2
Gastrinoma* 60 25e40 1e2
Glucagonoma 50e80 10 0.1
VIPoma 40e70 5 0.1
Somatostatinoma* 50e70 45 <0.1
Non-syndromic 60 20 1e2
*About half of cases arise in the duodenum.
MEN1, multiple endocrine neoplasia 1; NET, neuroendocrine tumour; VIPoma, vasoactive
intestinal peptide-secreting tumour.
Table 3 Clinical features of pancreatic NETs
Tumour Symptoms
Insulinoma Confusion, sweating, dizziness, weakness,
unconsciousness, relief with eating
Gastrinoma ZollingereEllison syndrome of severe peptic
ulceration and diarrhoea, or diarrhoea alone
23
Glucagonoma Necrolytic migratory erythema, weight loss,
diabetes mellitus, stomatitis, diarrhoea
VIPoma VernereMorrison syndrome of profuse watery
diarrhoea with marked hypokalaemia
Somatostatinoma Cholelithiasis, weight loss, diarrhoea and
steatorrhoea, diabetes mellitus
24
Non-syndromic pancreatic NET Symptoms from pancreatic mass and/or liver
metastases
NET, neuroendocrine tumour; VIPoma, vasoactive intestinal peptide-secreting tumour.
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(see also under Carcinoid heart disease).
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Carcinoid crisis
Carcinoid crisis is characterised by profound ﬂushing, broncho-
spasm, tachycardia and widely and rapidly ﬂuctuating blood
pressure. It is thought to be due to the release of mediators,
which lead to the production of high levels of serotonin and
other vasoactive peptides. It is usually precipitated by anaes-
thetic induction for any operation, intraoperative handling of
the tumour, or other invasive therapeutic procedures such as
embolisation and radiofrequency ablation.
Prognosis
NETs are slow-growing tumours and survival depends on
a number of factors. The highest 5-year survival rates in both the
SEER and NRC epidemiological studies were for patients with
rectal primary tumours (74e88%), while the lowest were found
among patients with pancreatic primaries (27e43%; table 4).
12 13
However, for patients with a benign insulinoma, the 5-year
survival rate may be over 95%.
38 It had been thought that
appendiceal NETs were relatively benign in their behaviour, yet
the SEER data have reported 5-year survival rates of 95%
for patients with localised disease and 35% for patients with
distant spread at the time of diagnosis.
12 The most recent SEER
and NRC data show that, overall, patients with appendiceal
primaries have 5-year survival rates between 70% and 80%.
13
The SEER data show that the 5-year survival of all patients
with NETs, regardless of the primary site and degree of spread,
did not change between 1973 and 2002 and remained at
60e65%. Over this period there may have been a slight
improvement in outcome for patients with a small bowel
primary, with an overall 5-year survival of w65% in 2002.
18 The
5-year survival among just over 4000 patients from England and
Wales presenting between 1986 and 1999 was 57% for those
with a well-differentiated tumour, and 5% for those with
a ‘small-cell’ tumour.
37
Length of survival is directly related to both the extent of the
disease at the time of diagnosis and the degree of differentiation of
the tumour. According to the most recent SEER data, the 5-year
survival of patients with well or moderately well-differentiated
tumours was:
< 82% for local spread.
< 68% for regional spread.
< 35% for distant spread.
For poorly differentiated tumours these values were lower:
< 38% for local spread.
< 21% for regional spread.
< 4% for distant spread.
14
The histopathological type of the tumour, its Ki-67 or MIB-I
proliferation index, size and location, as well as the age of the
patient, also affect survival.
13 14 39e45 It is no longer appropriate
to quote survival ﬁgures based on overall survival of all patients
with a tumour at a particular site. Such information, when
discussed with patients, should be based on a consideration of
the impact of the above factors.
Using the newer pathological classiﬁcation aids in the prog-
nostication of survival. Thus, the 5-year survival rates for grades
1, 2 and 3 tumours are 96%, 73% and 28%, respectively. Simi-
larly, using the recommended TNM staging system, 5-year
survival rates for stages I, II, III and IVare 100%, 90%, 79% and
55%, respectively, demonstrating the utility of such newer
classiﬁcations.
46
Genetics
NETs may occur as part of complex familial endocrine cancer
syndromes such as MEN1, MEN2,
47 neuroﬁbromatosis type 1
(NF1),
48 49 Von Hippel Lindau (VHL) and Carney complex,
although the majority occur as non-familial (ie, sporadic)
isolated tumours. The incidence of MEN1 in gastro-
enteropancreatic NETs varies from virtually nil in gut NETs, to
5% in insulinomas, to 25e30% in gastrinomas.
28 However, it is
important to search thoroughly for MEN1, MEN2 and NF1
syndromes in all patients with NETs by obtaining a detailed
family history and undertaking a clinical examination with
appropriate biochemical and radiological investigations. The
diagnosis can now be conﬁrmed by genetic testing. In addition,
mutations involving the succinate dehydrogenase subunit D,
which are usually associated with paragangliomas and phaeo-
chromocytomas, have been reported in patients with midgut
NETs.
50
A diagnosis of MEN1, MEN2, NF1 or a paraganglioma
syndrome not only has important implications for the patient
but also for the patient’s relatives, who should be considered for
screening for the associated tumours and genetic testing.
Gastrointestinal NETs may, on rare occasions, occur as an
isolated familial cancer, without evidence of a MEN syndrome.
51
This is consistent with results from epidemiological studies,
which show a small increased familial risk, with standardised
incidence rates of 4.35 (n¼4; 95% CI 1.86 to 7.89) for small
intestinal and 4.65 (n¼4; 95% CI 1.21 to 10.32) for colon NETs
in offspring of parents affected by NETs. This familial clustering
was seen to be more pronounced with midgut and hindgut
tumours, and very few patients had obvious MEN1, indicating
Table 4 Sites and overall 5-year survival rates in patients with gastroenteropancreatic NETs in the USA
(from the SEER Programme), Norway (from the NRC) and England and Wales
12e14 37
Site
Percentage surviving
SEER data (n[17312) England and Wales
Black patients White patients NRC data (n[2013)
Well-differentiated
tumours
Small cell
tumours*
Lung 36 48 54 ee
Stomach 56 64 45 52 18
Small intestine 64 70 59 59 27
Pancreas 27 35 43 39 17
Appendix 70 79 74 ee
Colon 61 53 41 65 27
Rectum 85 88 74 ee
*Data are for 1-year survival.
NET, neuroendocrine tumour; NRC, Norwegian Registry of Cancer; SEER, Surveillance, Epidemiology and End Results.
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Guidelinesthat much of this association is independent of MEN1.
10
Patients with tuberous sclerosis complex may also be at
increased risk of NETs.
52
A family history of cancer is also a signiﬁcant risk factor for all
typesofNETs.Riskiselevatedmoreofteninwomenthaninmen.
In a USA-basedcaseecontrol study,theadjusted ORs (95%CI) of
positive family history of cancer for small bowel, gastric, lung,
pancreatic and rectal NETs were 1.4 (0.9 to 2.2), 0.8 (0.3 to 2.6),
2.7 (1.2 to 6.1), 1.5 (0.8 to 2.9) and 1.8 (0.5 to 5.8) among men and
2.3(1.2to4.3),5.2(1.4to19.6),2.1(1.1to4.3),3.7(1.4to9.9)and
1.3 (0.4 to 3.0) among women, respectively.
20 Moreover, it
appears that up to w20% of patients with gastric NETs may also
develop another synchronous cancer, typically affecting the
gastrointestinal tract.
12 There are insufﬁcient data to know
whether this is a feature in patients with other NETs. Risks for
second cancers in men were increased during the ﬁrst year of
follow-up. Slightly lower risks were noted in women.
DIAGNOSIS
Diagnosis of NETs is based on clinical manifestations, peptide
and amine secretion,
53 and specialised radiological and nuclear
imaging. Diagnosis is secured by detailed histology, which
should be obtained whenever possible.
Biochemistry
The measurement of the secretory products of NETs is helpful in
three respects:
< To assist with initial diagnosis.
< To assess the efﬁcacy of treatment.
< To assess changing prognosis.
The life of patients with NET may be under more immediate
threat from the syndrome than from the underlying malignancy.
As the syndromes are driven by circulating secretory products, it
is usually beneﬁcial to reduce these.
Chromogranin A (CgA) is the only general marker for NETs as
it is usually found in high concentrations regardless of whether
the tumour is accompanied by hormone-related clinical
features.
29 54 55 However, chromogranin B (CgB) may be elevated
when CgA is in the reference range.
56e58 Two chromogranin
B assays are commercially available, from Euro Diagnostic UK
and Byorbyt Ltd. Pancreastatin, one of the post-translational
products of CgA, is a useful additional marker,
59 60 as it is only
raised in metastatic NETs and results are not confounded by
conditions that raise CgA (eg, treatment with proton pump
inhibitors, or atrophic gastritis).
Pancreatic polypeptide (PP), a product of the normal pancreas,
is secreted in high concentrations from a signiﬁcant proportion
of NETs throughout the gastroenteropancreatic tract (50e80%
of pancreatic NETs and >30% of all gut NETs). Therefore PP is
a useful additional or alternative general marker in some
circumstances, particularly when CgA or CgB are within the
reference range.
26 61
The measurement of speciﬁc markers is useful for the diag-
nosis and monitoring of speciﬁc tumours.
53
The majority of tumours of the jejunum, ileum, proximal
colon and appendix (>70%) and a signiﬁcant number of NETs of
the stomach and respiratory system (10e35%) secrete serotonin.
Reliable assay of serotonin in blood has been problematic, but is
performed in a few centres.
62 The breakdown product of sero-
tonin, 5-hydroxyindoleacetic acid (5-HIAA), has been used as an
alternative and may be readily measured in a 24 h urine collec-
tion. However, there are many dietary restrictions and drug
interference problems associated with the measurement of
serotonin and 5-HIAA, and the laboratory should be contacted to
ensure that inappropriate foods and drugs are excluded for 3 days
before and during the urine collection (online appendix 1).
As many tumours in the ileum and colon present with bowel
obstruction, and will have been resected surgically before diag-
nosis of tumour type, laboratory specimens are often collected
postoperatively. Urinary 5-HIAA may then be within the refer-
ence range. CgA and neurokinin A measurement,
63 together
with measurement of 5-HIAA, will indicate residual disease in
more than 90% of patients.
64 65 As surgical cure is rare, all of
these patients should be followed-up indeﬁnitely using labora-
tory testing (and imaging), with the exception of those with
some small tumours of the appendix (see under Surgery).
A range of peptide markers speciﬁc to the tumour site may
also be measured. These are detailed in table 5.
Laboratory diagnosis of some tumour types is not straight-
forward.
In the stomach, type I NETs are associated with atrophic
gastritis, while in type II NETs the gastrin results from a gastrin-
secreting tumour. Circulating gastrin is raised in both types I
and II, and causes enterochromafﬁn-like (ECL) cell hyperplasia
and, ultimately, may cause ECL NETs. In type III tumours,
gastrin is not raised. CgA is raised in all three types.
66 67
The laboratory diagnosis of gastrinoma may be difﬁcult. Both
gastrin and CgA are raised in gastrinoma. However, both gastrin
and CgA are also raised in many common conditions, particu-
larly when gastric acid is reduced or absentdfor example, in
patients with atrophic gastritis or in those receiving proton
pump inhibitor (PPI) therapy. Upper gastrointestinal endoscopy
and gastric biopsy is always required to differentiate gastrinoma
from atrophic gastritis; secretin stimulation and intragastric pH
may also be needed in some cases.
When circulating gastrin and CgA are raised, a fasting spec-
imen is required; autoimmune atrophic gastritis must be
excluded, and Helicobactor pylori should be eradicated. Recurrent
peptic ulcer disease, especially with gastrointestinal bleeding in
the absence of H pylori, gives a strong suspicion of gastrinoma.
PPIs and H2 antagonists raise both circulating CgA and gastrin
(online appendix 2). PPIs should be withdrawn with great
caution and ideally stopped 10 days to 2 weeks before any
planned estimation of circulating fasting gastrin. In patients
with suspected gastrinoma, oral H2 antagonists may be used
instead for this period, but it is advisable for these to also be
interrupted 48 h before the test.
68 Patients with a gastrinoma
should be advised that it is dangerous to stop PPIs without
supervision. Where a question regarding the diagnosis remains,
a secretin test may be performed, with or without gastric acid
studies.
Patients with gastrinoma may present with circulating gastrin
<10% above the reference range.
69 The majority of gastrinomas
are located in the duodenum rather than in the pancreas.
All patients with gastrinoma should be considered as candi-
dates for MEN1 syndrome. Fasting calcium, parathyroid
hormone and prolactin measurements should be made.
Insulinoma may be difﬁcult to diagnose, as circulating insulin
concentrations are often within the reference range in these
patients. The insulin level, however, will be inappropriate to the
blood glucose. Measurement of C peptide or pro-insulin is
helpful. The majority of insulinomas are benign, and CgA will
not be raised unless the tumour is metastatic. A 48e72 h fast
under hospital supervision with serial blood glucose analysis is
the gold standard diagnostic tool and will usually trigger
hypoglycaemia within 24 h. In w5% of patients, however, the
hypoglycaemia may only be revealed postprandially.
70
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and this may be a helpful marker in patients with these
tumours.
61
The majority of rectal tumours do not secrete CgA. Many
secrete PP and some may secrete enteroglucagon, human
chorionic gonadotropin-b or acid phosphatase. When a marker is
identiﬁed, this is helpful. However, the absence of a marker does
not equate to the absence of a tumour.
A range of peptide markers can be measured in two labora-
tories in the UK, and specimens may be sent to these labora-
tories through local hospitals. Some other NHS laboratories
measure CgA.
Some peptides show a signiﬁcant rise postprandially, partic-
ularly insulin, gastrin and PP. These peptides may remain
elevated for more than 6 h
71; therefore it is ideal that all speci-
mens should be collected after an overnight fast. For some of the
markers (eg, CgA), a fasting specimen is not required. If speci-
mens at clinics are not always collected after a fast, the fasting
or random status of the specimen should be recorded on the
accompanying form to enable appropriate interpretation by the
laboratory. With the exception of insulin, peptide markers for
NETs are all raised in the circulation of patients with renal
failure.
72 73 Interpretation of results from these patients is
difﬁcult.
A number of circulating markers have been reported to be of
prognostic value: CgA for the majority of tumours,
74
pancreastatin for hepatic tumour bulk,
59 and neurokinin A for
serotonin-secreting tumours of the small bowel.
64
In a signiﬁcant number of sporadic NETs, cell type may
change and tumours will produce different peptides in addition
to the original ones. This indicates worsening prognosis; in
particular, ACTH is associated with poor prognosis.
75e77
Circulating prognostic indicators are of value in progressive
disease and in assessing treatment response since they may be
repeated frequently.
IMAGING
Imaging is indicated at different stages in the patient’s care,
including:
1. Screening of at-risk populations
2. Primary lesion detection
3. Assessing extent of disease
4. Follow-up and assessing response to treatment.
Screening of at-risk populations
Patients with a family history of MEN1 syndromes should be
considered for screening according to the established MEN
syndrome guidelines.
78 In principle, screening of asymptomatic
family members should, where possible, be undertaken without
exposure to radiation, and thus ideally with MRI.
Primary tumour detection
Precise localisation and measurement of the primary tumour is
helpful for surgical planning. It is unclear whether locating and
resecting the primary tumour changes prognosis. However,
primary tumour resection may reduce the likelihood of local
complications, such as bleeding and obstruction.
Gastrointestinal and pulmonary NETs
Endoscopy is the investigation of choice for suspected gastric,
duodenal and colorectal NETs. EUS, where available, is a useful
adjunct for the assessment of depth of invasion and for biopsy
when a mass is detected.
79e81 CT and/or bronchoscopy are
Table 5 Peptide markers speciﬁc to the tumour site
Site Type Laboratory tests required Results expected
Gastric I and II CgA, gastrin Raised
III CgA, gastrin Raised CgA, gastrin not raised
Duodenal CgA, gastrin, PP, urinary 5-HIAA,
SOM
Raised CgA in 90%
Consider MEN1
Jejunal, ileal and
proximal colon
CgA, urinary 5-HIAA, NKA Raised CgA (>80%), U-5-HIAA (70%)
and/or NKA (>80%); see text
Proximal colon CgA, urinary 5-HIAA, NKA, (PP) Raised CgA (>80%), U-5-HIAA (70%)
and/or NKA (>80%); see text
Appendiceal CgA, urinary 5-HIAA, NKA, (PP) None raised unless metastatic
Metastatic: markers as ileal
Goblet cell CgA, urinary 5-HIAA, NKA, (PP) None raised
Rectal CgA, CgB, PP, glucagon, HCG-b Raised CgA (rarely); see text
Raised CgB, PP, glucagon and/or
HCG-b in some
Pancreatic CgA Raised CgA in metastatic tumours
only
Insulinoma CgA, insulin, blood glucose, Insulin inappropriate to glucose;
see text
C peptide or pro-insulin Raised C peptide and pro-insulin
Gastrinoma Gastrin Raised gastrin; see text
Glucagonoma Glucagon, enteroglucagon Raised glucagon
VIPoma VIP Raised VIP
Somatostatinoma SOM Raised SOM
PPoma PP Raised PP
MEN1 CgA, gastrin, (calcium, PTH),
insulin, glucagon, PP
Items in parentheses may be helpful for diagnosis and monitoring in individual patients.
CgA, chromogranin A; CgB, chromogranin B; HGC-b, human chorionic gonadotrophin b; 5-HIAA, 5 hydroxyindoleacetic acid; NKA,
neurokinin A; PP, pancreatic polypeptide; PTH, parathyroid hormone; SOM, somatostatin; VIPoma, vasoactive intestinal peptide-
secreting tumour.
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NETs.
82 SSRS and CT
83 provide additional staging information.
CT is the most widely used initial imaging investigation for
patients with a suspected gastrointestinal NET involving the
small bowel. The sensitivity for detection of the primary
tumour is limited (table 6), but mesenteric disease, lymphade-
nopathy and liver disease are well demonstrated.
93 94 The
technique of CT enteroclysis combines the cross-sectional
display of solid organs with the luminal and mural display of the
small bowel and is more sensitive than routine CT in demon-
strating an occult primary tumour in patients strongly
suspected of having a gastrointestinal NET of the small bowel.
Multiplanar reformatting facilitates viewing of the small bowel
loops. The reported sensitivity and speciﬁcity for detection of
small bowel lesions by CT enteroclysis is 85% and 97%,
respectively, and midgut NETs are well demonstrated.
84 95
Magnetic resonance (MR) enteroclysis is currently under inves-
tigation as a radiation-free alternative for small bowel assess-
ment.
85 96 Transabdominal ultrasound is no longer generally
used for the initial detection of gastrointestinal NETs.
Capsule endoscopy
Small-scale studies have reported the successful detection of
occult small bowel NETs using capsule endoscopy where other
techniques have failed.
96 97 It is advisable to use a dissolvable
‘patency’ capsule to safeguard against the capsule being retained
within strictures. A disadvantage of capsule endoscopy is that
precise localisation of the tumour within the small bowel is not
usually possible.
Pancreatic NETs
Functioning pancreatic NETs (ie, those associated with a
hormonal syndrome) may be picked up at an earlier stage than
non-functioning tumours. The potential for surgical cure
necessitates accurate localisation, ideally using a combination of
CT, MRI and EUS, often together with SSRS and, in some
centres, DSA with intra-arterial calcium stimulation. Meticu-
lous technique is required to optimise detection rate (online
appendix 3).
CT
With the development of multidetector CT (MDCT) and the
use of thin reformats, there has been a reported increase in
sensitivity for the detection of insulinomas to 94%.
86 When the
results of MDCT are combined with experienced EUS, a sensi-
tivity of 100% can be achieved.
86 Small functioning tumours are
usually isodense to pancreas before contrast and enhance
strongly after contrast, although the vascular blush is often
transient. The best visualisation is usually with arterial phase
imaging but portal venous phase imaging is complementary.
Large tumours are more likely to be non-functioning than small
tumours. Signs of malignancy include large size, necrosis,
calciﬁcation and invasion/inﬁltration of surrounding structures.
MRI
Marked improvements in MR technology have occurred in the
past decade. The diagnostic performance of MRI has improved
and has been shown, in several studies, to exceed or equal that of
CT.
87 98 99 MRI has a sensitivity of 94% for pancreatic lesions,
but this is lower for extrapancreatic lesions.
88 98
Pancreatic NETs are typically of high signal intensity on T2-
weighted and T2 fat-saturated images and of low signal inten-
sity on T1-weighted and T1 fat-saturated images. Enhancement
of a lesion following intravenous contrast administration may
render it isointense to the surrounding pancreatic parenchyma.
EUS
EUS is invasive, operator-dependent and is not available at all
centres. It greatly improves the sensitivity for the detection of
small tumours and multiple pancreatic NETs in MEN1 or VHL
syndromes compared with cross-sectional imaging.
100 101 The
primary aims of EUS are to obtain a tissue sample, and to decide
whether the patient should have an enucleation or a Whipple’s
procedure.
Although the diagnostic performance of EUS is operator-
dependent, reports indicate that overall the technique is highly
sensitive in experienced hands, with sensitivities as high as
79e100%.
101 102 There is a close correlation between aspiration
cytology and the ﬁnal histology after resection, and it has a low
complication rate.
103e106
Intraoperative ultrasound (IOUS)
This technique has similar advantages to EUS. IOUS may
improve the intraoperative sensitivity for identifying small
lesions in the pancreatic head and show multiple lesions in up to
92 97% in patients with the MEN1 syndrome; it may be
a useful adjunct to palpation of the gland.
107 108 IOUS has
the advantage over EUS of being able to assess the liver.
However, it is not as sensitive as surgical palpation in detecting
extrapancreatic lesions.
Intra-arterial calcium with DSA
This technique may be particularly important for localising
occult gastrinomas.
109 Intra-arterial calcium stimulation
combined with hepatic venous sampling has been reported to
achieve a success rate of up to 90% in the localisation of insu-
linomas. Results should be interpreted in combination with
those from other imaging modalities.
110 111
Scintigraphy (in all gastroenteropancreatic NETs)
Scintigraphy, including PET/CT, may be used to locate the
primary tumour in cases where endoscopic or CT ﬁndings are
inconclusive. These techniques are considered in the next
section.
Assessing extent of disease
Many patients with NET present with metastatic disease
without a known primary site. Investigations for localising the
primary site have been described above. In cases where CT has
Table 6 Sensitivities of the various imaging modalities for locating
speciﬁc NETs
80 84e92
Pancreatic NETs Tumour and Frequency
Dual-phase multi-detector CT 57e94%
MRI 74e94%
EUS 82e93%
SSRS insulinomas 50e60%
SSRS gastrin/VIP/somatostatin 75%
68Ga DOTATOC PET 87e96%
Primary gastrointestinal NETs
CT enteroclysis 85%
MR enteroclysis 86%
SSRS for detection of lesions in
non-pancreatic GI NETs
86e95%
Neuroendocrine liver metastases
CT 44e82%
MRI 82e95%
EUS, endoscopic ultrasound; GI, gastrointestinal; MR, magnetic resonance; NET,
neuroendocrine tumour; PET, positron emission tomography; SSRS, somatostatin receptor
scintigraphy; VIP, vasoactive intestinal peptide.
All of the above sensitivities for detecting tumour are further enhanced by intraoperative
ultrasound.
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lesion has been detected but whole-body imaging for the
detection of metastatic disease is indicated, whole-body scin-
tigraphy is indicated, using SSRS with single-photon emission
CT (SPECT) or PET/CT (using gallium-labelled somatostatin
analogues).
112 Imaging with SSRS or meta-iodobenzylguanidine
(mIBG) will also identify patients with inoperable or metastatic
disease who might be candidates for high-activity targeted
radiotherapy. Krenning et al
113 reported that SSRS before surgery
revised the staging and changed management in 33% of patients
with NET. In patients with poorly differentiated NET, [
18F]
ﬂuorodeoxyglucose (
18F-FDG) PET/CT may be helpful for
staging.
111Indium (
111I)-octreotide
The observation that NETs overexpress somatostatin receptors
(SSTRs) has led to the development of radiolabelled somato-
statin analogues for diagnostic imaging. Of the ﬁve recognised
receptor subtypes, SSTRs 2 and 5 have been targeted for imaging
purposes. SSRS is widely available and well established for the
localisation of primary NETs.
113e115 The reported sensitivity of
SSRS is 61e96%.
1 116e124 Sensitivity and speciﬁcity are
enhanced by topographic image acquisition (SPECT) and by the
recent development of SPECT/CT image fusion. In pancreatic
NETs, diagnostic performance varies by tumour type. Sensitiv-
ities approaching 75% have been reported for gastrinomas,
VIPomas, glucagonomas and non-functioning tumours,
compared with 50e60% for primary insulinomas.
89
Limitations of SSRS include: (1) reduced sensitivity in smaller
(sub-centimetre) lesions and in lesions exhibiting low receptor
density; (2) 2-day imaging protocol; and (3) potential interfer-
ence by co-adminstration of therapeutic somatostatin analogues
(online appendix 4). The demonstration of somatostatin
receptor status by
111In-octreotide or
68Ga-labelled peptide PET/
CT imaging positively predicts response to somatostatin
analogue therapy.
Meta-iodobenzylguanidine
NETs of pancreatic origin are rarely mIBG avid. In gastrointes-
tinal NETs of the small bowel,
123I-mIBG scintigraphy is less
sensitive than
111In scintigraphy.
125 126 The main indication for
mIBG imaging lies in selecting patients for high activity
131I-mIBG-targeted radionuclide therapy. Between 40% and 85%
of NETs accumulate mIBG depending on primary tumour origin.
PET/CT
68Ga somatostatin analogues
Several
68Ga-labelled somatostatin analogues have been devel-
oped for diagnostic imaging. DOTA octreotide (DOTATOC) and
DOTA octreotate (DOTATATE) bind to SSTR2 and SSTR5,
whereas DOTA-NaI-octreotide (DOTANOC) binds to SSTR2,
SSTR3 and SSTR5. Rapid tumour accumulation and background
clearance facilitate imaging within 100 min of administration.
90
In a study of 84 patients, the sensitivity (96%) and speciﬁcity
(92%) of
68Ga-DOTATOC proved superior to that of CT or
SSRS for detection of unknown primary, initial tumour
staging or follow-up after therapy. There was an increase in the
detection of unrecognised bone metastases, and additional
sites of metastatic disease were identiﬁed.
90 However, CT is
required to ensure detection of liver and lung metastases.
90 127 A
retrospective study of
68Ga-DOTATOC PET in duodenopancre-
atic NETs reported a sensitivity of 87% and a speciﬁcity of
83%.
91 68Ga-DOTANOC PET/CT has recently been reported to
have led to either staging or treatment change in 50 of 90
patients (56%) assessed prospectively.
128 The major practical
disadvantage of
68Ga-peptide PET/CT in the UK remains its
limited availability.
18F-FDG PET/CT
Although well-differentiated NETs are not typically
18F-FDG
avid,
18F-FDG PET/CT is useful in staging primary bronchial and
poorly differentiated aggressive NETs.
129
Emerging tools
18F-DOPA PET/CT (
18F-DOPA)
The sensitivity of
18F-DOPA in metastatic NETs approaches
100%, demonstrating more lesions than SSRS, CT, or SSRS and
CT combined. Carbidopa pretreatment is used to reduce arte-
facts related to physiological activity in the peripancreatic
tissues.
130
11C-5- Hydroxytryptophan (HTP) PET/CT (
11C-5HTP)
High detection rates are reported using
11C-labelled 5HTP for
both gastrointestinal and pancreatic NETs.
131 Pretreatment with
carbidopa is recommended.
132
At present, neither technique is routinely available in the UK.
Follow-up and assessing response to treatment
The role of follow-up imaging and optimal imaging frequency
depend on clinical circumstances and tumour grade.
133e135 The
modality of choice should be that which best demonstrated the
tumour at diagnosis. Thus, SSRS imaging is recommended for
tumours known to be SSTR-positive, supplemented by CT and
MRI where necessary. Follow-up for SSTR-negative tumours
relies on MDCTor MRI.
The follow-up interval depends on the rate of growth of the
tumour. Initially, follow-up imaging may be taken at
3e6-month intervals. If the disease is relatively slow growing,
the interval can be increased to 9e12 months. In slow-growing
tumours, particularly in younger patients, MRI may be used for
follow-up in order to to reduce radiation exposure to the patient.
In the context of clinical trials, standardised criteria may be used
to assess response, although these remain imperfect for the
evaluation of NETs. Functional MRI techniques, including
diffusion-weighted MRI and dynamic contrast-enhanced MRI,
are currently being evaluated.
ASSESSMENT OF QOL
Metastatic disease is a common presentation in patients with
NETs; therefore, often the aim of treatment is to improve QoL
rather than achieve a cure. It is therefore recommended that QoL
should be assessed regularly throughout management.
Patients with NETs, in spite of long-term and metastatic
disease, often perceive their health-related QoL as good,
136 but
the treatment options available to these patients are expensive
and are not without side effects. The data derived from QoL
measurement may be helpful to both patients and clinicians in
decisions about treatment options.
137 It can be used to help
inform economic analyses and resource allocation and to inﬂu-
ence healthcare policy.
138 QoL data may also be useful in high-
lighting those areas where we need to develop interventions for
the amelioration or prevention of treatment-related problems.
139
A speciﬁc QoL score questionnaire for patients with NETs is in
phase IV validation.
140 At present, the best tool to assess health-
related QoL in patients with NETs is the European Organization
for the Research and Treatment of Cancer’s Quality of Life
Questionnaire (EORTC QLQ) C-30.
141
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Pathological reporting of NETs
Pathologists dealing with NETs should have a special interest in
endocrine or gastrointestinal pathology, or participate in
a network with the opportunity for pathology review. Tumours
should be classiﬁed according to the WHO 2010 classiﬁcation.
142
This classiﬁcation is fundamentally different from the WHO
2000 classiﬁcation scheme,
143 as it no longer combines stage-
related information with the two-tiered system of well and
poorly differentiated NETs. The WHO 2010 classiﬁcation is
based on the concept that all NETs have malignant potential,
and has therefore abandoned the division into benign and
malignant NETs and tumours of uncertain malignant potential.
Instead, it organises the classiﬁcation of NETs according to grade
and stage. The classiﬁcation scheme uses the terms NET (or
neuroendocrine neoplasm) and neuroendocrine carcinoma as
outlined in table 1 of online appendix 5.
Grading is performed on the basis of morphological criteria
and the proliferative activity of the tumour (online appendix 5).
Tumour staging is performed according to a system of site-
speciﬁc criteria. While the WHO 2010 classiﬁcation recommends
using the Union for International Cancer Control (UICC) TNM
(7th edition) staging system,
144 it acknowledges the existence of
the ENETS staging system,
145 146 and the fact that grading and
staging deﬁnitions may need adjustment in the future as the
schemes evolve.
The ENETS TNM staging system for gastrointestinal
and pancreatic endocrine tumours has been described
previously.
145 146 The T-staging criteria differ from those
proposed by UICC TNM (7th edition)
144 for gastric and
pancreatic NETs, and in particular, for NETs of the appendix.
The recommendations are therefore:
1. To grade the tumour according to the WHO 2010 grading
system
142
2. To stage the tumour according to the UICC TNM (7th
edition)
144 site-speciﬁc system
3. To also stage the tumour according to the ENETS site-speciﬁc
T-staging system when different from the UICC TNM (7th
edition)dthat is, for NETs of the stomach, pancreas and
appendix
145 146
4. To state which TNM classiﬁcation is used
5. To document the underlying features that contribute to the
T-stage classiﬁcation (eg, tumour size, extent of invasion, etc)
to allow translation between different current and future
classiﬁcation systems.
147
In addition, pathologists should refer to the WHO 2000
classiﬁcation
143 for those NETs that, according to this system,
fall into the category of benign tumours. This is applicable to
NETs that are small and locally conﬁned without distant spread,
and relates in particular to a proportion of pancreatic insuli-
nomas, gastric NETs in the context of chronic atrophic gastritis,
and incidental appendiceal NETs. The benign behaviour of these
NETs is widely accepted and established in clinical practice, and
it is therefore deemed clinically useful to report on this addi-
tional information at a time of transition between both classi-
ﬁcation systems.
The prognostic validity of the TNM system as proposed by
ENETS has been established,
46 148e152 but similar validation
studies are still awaited for the recently introduced WHO 2010
and UICC TNM (7th edition) classiﬁcation and staging schemes.
Specimen handling, and gross and microscopic assessment
should be carried out according to a standard protocol that is
based on the Royal College of Pathologists dataset for NETs of the
gastrointestinal tract and pancreas
153 and that follows the ENETS
consensus guidelines.
154 Further detailed recommendations are
given in online appendix 5.
TREATMENT
Objectives
The aim of treatment should be curative where possible but it is
palliative in the majority of cases. Patients often maintain a good
QoL for a long period despite having metastases. Although rate
of growth and malignancy are variable, the aim should always
be to maintain a good QoL for as long as possible. For all
patients, the aim is to keep the patient free from disease and
symptoms for as long as possible.
Surgery
General approach
Surgery is the only curative treatment for NETs. As with all
gastrointestinal tumours, the conduct of surgery with intent to
cure depends on the method of presentation and the stage of
disease. Speciﬁc issues with NETs include determining the
extent of local and distant tumours, identiﬁcation of synchro-
nous non-NETs, recognition of ﬂuid and electrolyte depletion
from diarrhoea, and, in advanced cases, detection of less obvious
cases of carcinoid syndrome as well as detection of cardiac
abnormalities. The treatment plan should be modiﬁed accord-
ingly, whether to meet immediate or long-term objectives,
within a multidisciplinary framework. With NETs, if the
primary lesion is <2 cm in diameter (depending on the site of
origin), the incidence of metastasis is low.
30 155 However, nodal
or liver metastases are found at presentation in 40e70% of
patients.
30 155e157
Perioperative preparation of patients with functional NETs
When major surgery or hepatic artery embolisation are planned
in patients with carcinoid syndrome, prophylactic administra-
tion of somatostatin analogues should be considered to prevent
a potential carcinoid crisis, even in patients who are receiving
long-acting formulations of these agents. Short-acting octreotide
is preferably used by constant intravenous infusion at a dose of
50 mg per hour, initiated 12 h before, and given for 24e48 h after,
surgical intervention.
158e163 It is also important to avoid drugs
that release histamine or activate the sympathetic nervous
system.
164 Despite octreotide therapy, patients may still
develop life-threatening cardiorespiratory complications that
can tax even the most experienced anaesthetist, who may have
to use a- and b-adrenoreceptor blocking drugs to avoid severe
complications.
165
In addition, short-acting octreotide should always be avail-
able, even when a non-syndromic patient with a small bowel
NET undergoes an interventional procedure. In cases of unex-
pected carcinoid crisis, bolus intravenous doses of 100e500 mg
octreotide should be given, followed by continuous infusion (see
doses above). Antihistamines and corticosteroids may also be
beneﬁcial.
35
Similar prophylactic measures may be required for pancreatic
and periampullary NETs, for example glucose infusion for
insulinoma, PPI (oral or infusion) and intravenous octreotide for
gastrinoma.
Lung
The treatment of choice is a major lung resection or wedge
resection plus node dissection.
166 Direct bronchial ultrasound
may assist in determining the resection margin.
167 Five-year
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on the histology of the tumour
168e171 and the extent of lymph
node involvement.
172e178
Emergency abdominal presentations
Patients presenting with suspected appendicitis, intestinal
obstruction or other gastrointestinal emergencies are likely to
require resections sufﬁcient to correct the immediate problem.
Once deﬁnitive histopathology is obtained, a further, more
radical resection may have to be considered. The most common
circumstance is when a NET arising in the appendix 2 cm or
more in diameter has been removed. Under these circumstances,
a right hemicolectomy is usually indicated, despite the common
absence of obvious malignant features characterising the
NET.
179e181 Goblet cell appendix tumours always require right
hemicolectomy because they behave in a much more aggressive
way.
182e184
Well-differentiated tumours that are <2 cm may require
further resection if they:
< Breach the serosal surface
< Invade the mesoappendix by more than 3 mm
< Are located at the base of the appendix.
185
There is no deﬁnite evidence for the requirement of further
surgery if histology shows vascular, neural or lymphatic inva-
sion, but close follow-up is advisable, and further surgery could
be discussed with the patient.
Most patients should be followed-up for 10 years.
186
Complete resection by appendicectomy of lesions smaller than
1 cm in diameter with no other adverse features is likely to be
curative.
180 Extended follow-up in this case does not appear to
be necessary.
If a perforation has occurred at the site of the tumour, some
authorities would recommend right hemicolectomy, although
there is no direct evidence relating to this.
Practice point
Although not underpinned by any evidence from prospective
studies, the guideline development group holds the view that,
particularly in women, there is an increased risk of pelvic peri-
toneal metastases (especially bilateral ovarian) with goblet cell
NETs of the appendix. Such patients should therefore be coun-
selled about this risk and the provision of ‘prophylactic’ bilateral
oophorectomy should be discussed.
185 187 188
Level of evidence 5, Grade of recommendation C.
A limited emergency small bowel resection for an obstructing
NETcan be followed at a later date by elective surgery to remove
further small bowel or to undertake mesenteric lymphadenec-
tomy. This is particularly appropriate if a second tumour has
been identiﬁed. A substantial minority of patients with midgut
NETs have multiple tumours,
189 190 so a search should be made
after removal of an obstructing lesion before any further surgery.
Furthermore, it is not uncommon to encounter signiﬁcant
desmoplastic reaction in the mesentery (occasionally with
varices), which renders resection extremely difﬁcult and
dangerous in inexperienced hands. In such cases it is not
unreasonable to refer intervention on to a surgeon with greater
experience of midgut NETs.
Level of evidence 3e5, Grade of recommendation C.
Stomach
In patients with gastric NETs, the surgical approach depends on
the type of tumour, of which there are three types.
Type 1 gastric NETs are associated with hypergastrinaemia and
chronic atrophic gastritis. They originate from ECL cells, and can
synthesise and store histamine. The frequency of direct invasion
into muscularis and metastasis is extremely low, and in most
cases only annual endoscopic surveillance is appropriate.
191e195
Limited surgery with endoscopic polypectomy and/or antrec-
tomy may be preferable, especially when B12 deﬁciency anaemia
is compounded by iron-deﬁciency anaemia due to bleeding
from the gastric NETs,
191 196e198 although achlorhydria also
contributes to iron deﬁciency due to iron malabsorption.
Type 2 gastric NETs occur in patients with hypergastrinaemia
due to ZollingereEllison syndrome in combination with MEN1
syndrome.
199 Small type 1 and 2 tumours with no extension into
muscle on EUS or CT can be resected endoscopically, and
a combined laparoscopic and endoscopic technique has been used.
Type 3 gastric NETs are sporadic and have a more malig-
nant course.
192 200 They are not associated with hyper-
gastrinaemia. These tumours have often metastasised at the
time of diagnosis. Most lesions will need resection and clearance
of regional lymph nodes and are effectively treated as for gastric
adenocarcinoma.
191 201e203
Level of evidence 3e5, Grade of recommendation C.
Small intestinal NETs
By far the majority of small intestinal NETs are malignant in
nature. Whether liver metastases are present or not, resection of
the primary tumour and extensive resection of associated
mesenteric lymph nodes is appropriate to cure or to delay
progression that would otherwise endanger the small bowel.
Occasionally, nodal metastases cause sclerosis with vascular
compromise of the associated small bowel, which can lead to
pain, malabsorption and even death. Patients who are discovered
to have small intestinal NETs only after laparotomy and histo-
logical examination may be candidates for further surgery,
notably for extensive mesenteric lymphadenectomy. Resection
of mesenteric metastases may alleviate symptoms dramatically
and, in large series, is associated with prolonged survival. It is
recommended that such surgery is undertaken in centres where
surgeons have experience of operating on patients with midgut
NET disease.
Level of evidence 2, Grade of recommendation B.
As yet there is no clear guidance on the role of resection of
asymptomatic primary NETs in the presence of unresectable
liver metastases; ideally this question should be answered by
a randomised controlled trial. Data from a UKINETS audit
204
and other authors
205 suggest that there may be a survival beneﬁt
for such practice.
Level of evidence 4, Grade of recommendation C.
Colorectum
Standard resection with locoregional lymphadenectomy is
appropriate.
206 Clearance of metastatic lymph nodes is
a worthwhile objective that may contribute to long-term
survival, and nodal clearance does not add signiﬁcantly to the
risk of mortality, which should in any case be <2% when
conducted by specialist colorectal teams. Small lesions that are
<1 cm in diameter and that have a well-differentiated histology
(particularly those in the rectum, which tend to have a less
aggressive course) may be considered adequately treated by
complete endoscopic removal or transanal mucosal resection;
however, the patient will require follow-up endoscopy to ensure
this has been accomplished. Lesions that are more than 2 cm in
diameter should be managed as per adenocarcinoma; there is
debate concerning lesions of 1e2 cm, but some of these will
invade locally and metastasise.
Level of evidence 3, Grade of recommendation C.
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Pancreatic and periampullary NETs form a special group that
requires particular consideration.
207e212 As with all other
neoplasms at these sites, surgery should only be undertaken in
specialist hepatopancreatobiliary units. It is recognised that
pancreatic resectional surgery is increasingly being performed via
laparoscopic access.
213e216 For the moment, the decision as to
whether this surgery is performed by the traditional open or
laparoscopic route should be left to the discretion of each
designated specialist pancreatic surgery centre.
According to the WHO classiﬁcation, tumour size correlates
with malignant potential. Localised tumours larger than 2 cm in
diameter warrant aggressive resection. Surgical management
remains to be proven effective for non-functioning pancreatic
NETs in MEN1 syndrome. Often the diagnosis is established
biochemically before surgery and, although preoperative local-
isation can be difﬁcult, the biochemical diagnosis provides some
indication of the likelihood of malignancy (eg, low with insuli-
noma), and localisation can be aided by hepatic venous sampling
after calcium stimulation. Thus, for insulinoma, if the lesion is
clearly localised before surgery, and is near or at the surface of
the pancreas and easily deﬁned at surgery, enucleation may be
sufﬁcient, provided histopathology demonstrates complete
excision and benign features.
217 However, this may not be
possible, and KauscheWhipple pancreatoduodenectomy, left
pancreatectomy or even total pancreatectomy may be justiﬁed
in selected cases.
218 These operations are also applied to selected
cases with localised disease arising from other functioning, as
well as non-functioning, NETs of the pancreas.
219
In patients with ZollingereEllison syndrome who do not have
MEN1 syndrome, surgical exploration should be offered for
a possible cure of the disease. There is controversy concerning
patients with this syndrome who have MEN1, however, since
older data suggest poorer survival in patients treated surgically.
220
Nevertheless, the majority of these patients die from malignant
spread of their gastrinomas, suggesting that resection is prefer-
able for tumours 2 cm or larger to prevent metastatic spread.
221
Level of evidence 3, Grade of recommendation B.
With advances in diagnostic imaging, small non-functioning
(<2 cm) pancreatic NETs are increasingly being diagnosed in
asymptomatic, otherwise well patients.
222 223 While, intuitively,
such patients should beneﬁt from surgical resection of such
tumours, the management of these patients remains contro-
versial. In the absence of consensus, these patients should be
managed by an expert MDTexperienced in the management of
pancreatic NETs.
Level of evidence 4, Grade of recommendation C.
While there is evidence to support hepatectomy for resectable
NET liver metastases,
224 the role of resection of asymptomatic
primary pancreatic NETs in the presence of unresectable liver
metastases remains controversial.
225 In the absence of adequate
evidence, such decisions should be made by an expert MDT
experienced in the management of pancreatic NETs.
Level of evidence 4, Grade of recommendation C.
Appendix
The appendix is a common primary site, with tumours often
found incidentally at appendicectomy. Some 75% of these NETs
are located near the tip. Classical NETs <1 cm in size can usually
be managed by appendicectomy, while for tumours >2c mi n
size or for goblet cell tumours of any size, right hemicolectomy
is the treatment of choice.
184 226e228 For tumours 1e2c m i n
size, any of the following mandates right hemicolectomy:
serosal breach by tumour, cellular atypia, invasion of
mesoappendix by more than 3 mm, or involvement of the base
of the appendix.
229 230 Some centres recommend right hemi-
colectomy for perforation of the appendix in the presence of
a NET and for lymphovascular and perineural invasion, but no
deﬁnite evidence exists. Long-term (10-year) follow-up is
required for any high-risk features.
Level of evidence 3e4, Grade of recommendation C.
Liver
In the presence of liver metastases ‘curative’ liver resection is
possible in about 10% of cases,
224 if the lesion(s) is conﬁned to
one lobe. With bilobar metastases and one very dominant lesion
causing symptoms, a debulking operation may be carried out for
palliation, particularly if there is resistance to medical therapy.
The 5-year survival after resection of the primary and/or liver
secondary is up to 87%, and postoperative mortality is
6%.
161e163 231e236 Several series have shown low morbidity and
excellent medium-term survival after liver resection, with better
outcomes than for patients whose tumours are not resected
(although this may partly reﬂect stage of disease).
231 237 238 A
very small number of patients with no obvious primary tumour
may have primary hepatic neuroendocrine malignancy, and
surgery can be curative
239; for such patients, surgery is the
treatment of choice, with a recurrence rate of 18% and 5-year
survival of 74% reported in one series.
240 Many patients will
need somatostatin analogues, which predispose patients to
gallstones, hence the gallbladder is usually removed at the time
of liver surgery.
Level of evidence 3, Grade of recommendation B.
Orthotopic liver transplantation (OLT)
Patients with end-stage NETand uncontrollable symptoms that
are unresponsive to any other therapy have been considered for
liver transplantation.
241e248 The highest disease-free survival
reported to date at 1 year is 77%.
247
An analysis of UK transplants for NETs
249 reported actuarial
disease-free survival of 62% at 1 year and 23% at 5 years, with
similar data in a series from France.
250 The UK and French series
both included patients from many years ago, when survival rates
would be expected to be lower, and many patients in these series
predated modern imaging techniques. More recent data from the
French group
251 252 show 5-year survival at 47%, which is close
to the acceptable limit for transplantation in the UK.
OLT is currently outside the routine remit of UK Transplant
Agency guidelines in view of the disease-free survival of <50% at
5 years. However, survival has progressively increased
245e247
such that in the future, in selected patients and using new drug
treatments, OLT may be a management option. At present, only
exceptional cases that cannot be treated by other means should
be considered, and this should preferably be part of a national
trial so that data are standardised and examined regularly. OLT
should be avoided in patients who have undergone multiple
organ transplants, and those who have pancreatic primary sites
and high Ki-67-expressing tumours.
At present, organ shortage combined with the low survival
data suggest that liver transplantation should only be considered
in exceptional circumstances. Further research is needed to try to
assess pretransplant prognostic factors.
Symptomatic treatment
Symptoms associated with NET hormonal hypersecretion
may impair patients’ QoL and in some instances can be life-
threatening (eg, severe diarrhoea and hypokalaemia in VIPomas).
Administration of speciﬁc medications to treat symptoms
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Guidelinesshould therefore start as soon as clinical and biochemical signs
indicate the presence of hypersecretory NETs, even before the
precise localisation of primary and metastatic lesions is
conﬁrmed. Treatments include somatostatin analogues, and the
use of PPIs for gastrinomas and diazoxide for insulinomas.
Additional medications such as loperamide, cholestyramine and
corticosteroids may be used as required.
Somatostatin analogues
The only proven hormonal management of NETs is by the
administration of somatostatin analogues. SSTRs are present in
the vast majority (75e95%) of NETs, but are identiﬁed in only
50e60% of insulinomas, and are less evident in poorly differ-
entiated NETs and somatostatinomas. Since natural somato-
statin has a very short half-life (2e3 min), analogues with longer
half-lives have been developed for clinical use. Somatostatin
analogues bind principally to SSTR subtypes 2 (with high
afﬁnity) and 5 (with lower afﬁnity),
253 thus inhibiting the
release of various peptide hormones in the gut, pancreas and
pituitary; they also antagonise growth factor effects on tumour
cells, and, at very high dosage, may induce apoptosis. The effects
of somatostatin analogues are demonstrable as biochemical
response rates (inhibition of hormone production) in 30e70% of
patients and as symptomatic control in the majority of patients.
There are two commercially available somatostatin analogues:
octreotide and lanreotide. The immediate-release form of octreo-
tide (half-life of 1.5e2 h) has to be administered subcutaneously
two to three times per day or by continuous intravenous infusion.
Longer-acting (slow-release and depot) formulations of somato-
statin analogues include octreotide long-acting release (LAR),
lanreotide Autogel and lanreotide LA.
254 The long-acting agents
have produced signiﬁcant improvement in the QoL of patients
with NET and have comparable or better efﬁcacy than short-
acting octreotide.
255e258 Long-acting formulations of somato-
statin analogues should therefore now be considered the standard
of care for symptomatic treatment of NETs. Short-acting
formulations may still have a role in patient stabilisation (used
over short periods) and in the management of carcinoid crisis.
The licensed dosage of octreotide LAR is 10, 20 or 30 mg every
4 weeks, and for lanreotide Autogel the recommended dose is 60,
90 or 120 mg every 4 weeks. Patients should generally be started
on lower doses with treatment up-titrated to achieve stabilisa-
tion. In cases of breakthrough symptoms, rescue doses of
subcutaneous octreotide can be used two or three times per day
up to a maximum daily dose of around 1 mg. Alternatively, if the
breakthrough symptoms occur mainly during the week before
the next long-acting injection, a reduction of administration
intervals from 4 to 3 weeks may be considered.
259
Role in prevention of carcinoid crisis
See under ‘Perioperative preparation of patients with functional
NETs’ for an overview of the use of somatostatin analogues in
the prevention of carcinoid crisis.
Nuclear medicine imaging and treatment with radiolabelled
somatostatin analogues during treatment with somatostatin
analogues
In theory, co-administration of somatostatin analogues may
reduce the sensitivity of SSRS imaging. Where possible, most
UK centres recommend withdrawal of short-acting somato-
statin analogues for 24e48 h before
111In-octreotide or
68Ga-peptide injection until imaging is completed.
In patients receiving long-acting analogues, SSRS or
68Ga PET/
CT, studies should ideally be scheduled towards the end of the
dosing interval and just before the next planned injection.
ENETs guidelines suggest withdrawing long-acting somato-
statin analogues for 6 weeks before planned radiopeptide
treatment, and substituting short-acting somatostatin
analogues for symptom control until 24 h before treatment.
260
In the absence of evidence from randomised controlled trials,
most UK centres avoid the potential morbidity of this
approach by adhering to the simpler regimen described above
for diagnostic imaging.
Somatostatin analogue treatment does not interfere with
mIBG or
18F-FDG PET/CT imaging.
Adverse effects
The most common adverse effects of somatostatin analogues are
usually mild and resolve with time.
8 261 262 They include local
reactions (pain and erythema) at the injection site, abdominal
cramps, nausea, ﬂatulence, diarrhoea and steatorrhoea. There is
also a risk of cholelithiasis (10e50%),
263 264 which may be
asymptomatic; in such cases, cholecystectomy is not necessary.
However, prophylactic cholecystectomy during abdominal
surgery is recommended in patients who are already receiving, or
are due to start, long-term treatment with somatostatin
analogues.
265 Rare adverse effects include bradycardia, abnormal
metabolism of glucose, malabsorption of vitamins A, B12 and D,
and alopecia.
266
Efﬁcacy and indications in various syndromes
Functioning small bowel NETs (carcinoid syndrome). Somatostatin
analogues are effective in the management of the symptoms of
carcinoid syndrome. Most studies report improvements in diar-
rhoea and ﬂushing in 60e70% and 70e80% of patients, respec-
tively, and a signiﬁcant reduction (>50%) in biochemical
markers (especially 5-HIAA) in 40e60% of patients.
123 256 267
VIPoma (watery diarrhoea, hypokalaemia, achlorhydria (WDHA)
syndrome, WernereMorrison syndrome)
Rehydration and electrolyte replacement are always indicated
and may improve the clinical condition considerably. In patients
with this rare life-threatening syndrome, the administration of
somatostatin analogues results in signiﬁcant improvement of
symptoms in 80e90% of patients and in reduction of vasoactive
intestinal peptide levels in 60e80%.
268 269 However, biochemical
improvement does not always correlate with symptomatic
improvement, and thus the drug dose should be titrated mainly
against symptoms.
Glucagonomas
Somatostatin analogues have been reported to result in
improvements in patients with the glucagonoma syndrome
(migratory necrolytic erythema rash, diabetes, weight loss, etc).
The characteristic rash of necrolytic migratory erythema can be
life-threatening. After the initiation of somatostatin analogue
treatment, 80e90% of patients with glucagonomas show
a signiﬁcant improvement in migratory necrolytic erythema
rash. Treatment is less effective in terms of controlling diabetes
and weight loss, which are common symptoms in these
patients. Treatment with somatostatin analogues may result in
a reduction in circulating glucagon levels in about 60% of
patients, although in many cases these levels are very high, so
normalisation is unlikely.
258 270
Gastrinomas
PPIs are currently the treatment of choice for the control of
gastric acid hypersecretion-associated symptoms (see under
Proton pump inhibitors). Somatostatin analogues are not
considered as ﬁrst choice agents by the majority of clinicians and
should only be used in refractory cases.
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Somatostatin analogues are often not effective in the control
of hypoglycaemia in patients without SSTR 2-positive
tumours (50e60% of insulinomas), and their use may lead to
variable effects on blood glucose levels, possibly because
of inhibition of glucagon secretion.
271 272 Diazoxide has
been shown to be effective in controlling hypoglycaemic
symptoms in many patients with insulinoma (see under Other
medications).
273
Other clinical syndromes
Somatostatin analogues have been reported to improve para-
thyroid hormone related peptide (PTHrP)-related hyper-
calcaemia in rare PTHrP-secreting pancreatic NETs.
274 They may
also be beneﬁcial in NETs patients with paraneoplastic Cush-
ing’s syndrome or acromegaly, associated with ectopic secretion
of ACTH or growth hormone-releasing hormone (GHRH),
respectively.
275 276
Non-functioning NETs
The role of somatostatin analogues in patients with non-
functioning NETs is unclear and the routine use of these agents
in such NETs can only be recommended once further evidence is
available.
Antiproliferative potential of somatostatin analogues
It has been postulated that somatostatin analogues may have an
antiproliferative effect. Several studies suggest that, in pancre-
atic NETs, partial/complete tumour response is achieved in
fewer than 10% of patients, although stabilisation of radiologi-
cally documented tumour progression has been demonstrated in
24e57% of patients.
277e284
Similar results have been demonstrated for small bowel
NETs.
256 257 267 277e283 In addition, recent data from one double-
blind, placebo-controlled study (PROMID; Placebo-controlled,
double-blind, prospective, Randomised study on the effect of
Octreotide LAR in the control of tumour growth in patients
with metastatic neuroendocrine MIDgut tumours) demon-
strated prolonged progression-free survival (PFS) in patients
with metastatic NETs of midgut origin receiving octreotide LAR
with a median time to progression of 14.3 months compared
with 6 months in the placebo group. In this study, the best
results were demonstrated in patients with low hepatic tumour
load and a resected primary lesion.
285
Finally, there is an ongoing study assessing the anti-
proliferative effects of lanreotide Autogel in patients with non-
functioning intestinal and pancreatic NETs.
While the evidence is thus not wholly conclusive, and further
studies in a wider range of tumours and using different doses
will be valuable, at present there is a rationale for the use of
somatostatin analogues in attempting to moderate the tumoural
progression of NETs.
New somatostatin analogues
New somatostatin analogues are in development, with the agent
SOM-230 (pasireotide) in phase II at the time of writing. These
studies may extend the use of somatostatin analogues for
symptomatic therapy, and may offer treatment for patients
resistant to conventional octreotide and lanreotide.
Proton pump inhibitors
PPIs are currently the treatment of choice for the control of
gastric acid hypersecretion-associated symptoms and prevention
of peptic complications in gastrinoma patients. Higher doses of
PPIs may be required in patients with complicated disease.
Other medications
Diazoxide is used as short-term treatment in patients with
insulinoma scheduled for surgery, or as a long-term therapy in
patients with unresectable disease. Diazoxide is a hypertensive
medication with hyperglycaemic effects, and is usually effective
in controlling hypoglycaemia symptoms in patients with insu-
linoma. The recommended daily dose is 200e600 mg orally.
Adverse effects, including oedema, weight gain, hirsutism and
renal dysfunction, are common but are not usually trouble-
some.
273 There are two small case series of patients with
malignant insulinoma refractory to conventional agents that
report signiﬁcant improvement in glycaemic control with the
novel mammalian target of rapamycin (mTOR) inhibitor, ever-
olimus,
286 287 and also a case report of a similar patient showing
control of hypoglycaemia with oral rapamycin.
287
In patients with small bowel NETs, loperamide and ondan-
setron can be used for the management of secretory diarrhoea,
cholestyramine for bile salt malabsorption-related diarrhoea, and
oral pancreatic supplements for steatorrhoea following treat-
ment with somatostatin analogues. Oral antibiotics may be used
for control of small bowel bacterial overgrowth in patients with
extensive mesenteric ﬁbrosis. Patients may also beneﬁt from oral
vitamin B compounds to prevent clinical features of vitamin B
deﬁciency.
In some patients with insulinoma, verapamil and phenytoin
can be used as alternatives to diazoxide. Corticosteroids can be
used in patients with insulinoma with refractory hypoglycaemia
and in those with VIPoma with life-threatening diarrhoea that
does not respond to maximum doses of somatostatin
analogues.
288
In patients with glucagonoma, zinc salts can be used to
prevent further skin lesions.
Appropriate prophylaxis should be considered in all patients
with NETs with increased risk of thromboembolic episodes (eg,
those with glucagonoma).
Bisphosphonates may be used for symptom control in
patients with bone metastases, although they are not speciﬁ-
cally indicated for NETs.
289
Interferon a
Interferons are immune modulators necessary to combat viral
infections. Interferon a acts via speciﬁc cell-surface receptors to
activate downstream cytoplasmic kinases. In addition, it induces
arrest in the G1 and G0 phases of the cell cycle, inhibits
production of growth factors, induces class 1 antigens, and has
antiangiogenic properties.
290 It is used for the treatment of both
functional and other NETs, either on its own or added to long-
acting somatostatin analogues if the patient is not responding to
maximum dosage of somatostatin analogues. Interferon a 3e5
mega units three times per week subcutaneously is the usual
dose used. However, there is conﬂicting evidence as to its efﬁ-
cacy, with only one major group supporting its widespread use.
However, there is some evidence that it may have a greater effect
in tumours with low mitotic rate.
266 Biochemical response has
been demonstrated in 40e60% of patients, while symptomatic
improvement and signiﬁcant tumour shrinkage have been
reported in 40e70% and a median of 10e15% of patients,
respectively.
291e293
Somatostatin analogues have been added to interferon a with
the aim of enhancing its antitumour effect,
294 but studies thus
far have failed to demonstrate this. An increase in 5-year survival
from 37% with interferon a alone to 57% in combination with
octreotide was seen in one study (HR 0.62 (95% CI 0.3 to 1.1);
p¼0.132), although the results were not statistically signiﬁcant
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295 Two other small
randomised studies have shown this combination to increase
toxicity without any additional survival beneﬁt (although both
studies were underpowered to do so).
296 297 Although sometimes
useful for control of refractory hormonal symptoms, the
combination of interferon a and somatostatin analogues for the
prolongation of survival should still be considered investigational.
Emerging evidence suggests that pegylated interferon is better
tolerated and also demonstrates some activity
298 299; however,
current data do not support its use outside of clinical trials.
Chemotherapy
There are only four published randomised trials of chemo-
therapy for NETs, and none have compared chemotherapy with
best supportive care.
300 301 There are numerous small, uncon-
trolled, retrospective studies in heterogeneous or poorly charac-
terised patient populations. Many older studies report response
rates in terms of clinical, radiological and biochemical response
rather than according to WHO or RECISTcriteria.
302 303
For pancreatic NETs the seminal randomised trials performed
by Moertel et al
304 305 established streptozotocin (STZ)-based
regimens as the standard of care. The ﬁrst trial demonstrated
a superior, but non-signiﬁcant, survival beneﬁt for patients
treated with the combination of STZ and 5-ﬂuorouracil (5-FU)
compared with STZ alone,
304 while the second showed better
survival for the combination of STZ and doxorubicin (DOX;
26 months) over single-agent chlorozotocin (18 months) or the
5-FU/STZ combination (17 months).
305 In these trials, the best
response rates were 63% and 69%, respectively, but these rates
were based on clinical and biochemical responses as well as
radiological response.
A more realistic response rate is provided by three recent
single-arm studies, which applied WHO or RECIST criteria in
patient cohorts of at least 45 patients. Using STZ/DOX,
306
STZ/5-FU/DOX
307 or STZ/5-FU/cisplatin (FCiSt),
308 response
rates were remarkably consistent at 36%, 39% and 38%, and
were associated with median overall survival of 24, 37 and
32 months, respectively. The results of the recently completed
randomised phase II NET01 trial comparing STZ/capecitabine
with or without cisplatin (FCiSt; http://Clinicaltrials.gov
identiﬁer NCT00602082) are awaited.
Temozolomide (TMZ), like STZ, is an alkylating agent but is
orally bioavailable, and has been reported to have a 70% response
rate in a recent small (n¼30) single-arm study when used in
combination with capecitabine.
309 Previous results using TMZ
as a single agent or in combination with thalidomide or beva-
cizumab have been less impressive,
310 311 and randomised
comparisons with STZ regimens are required. Of interest,
response to TMZ may be related to expression of the DNA
repair enzyme methylguanine DNA methyltransferase
(MGMT), and two small retrospective studies have shown
increased responses to TMZ by MGMT-deﬁcient tumours.
311 312
The value of MGMTexpression as a potential predictive marker
of response of NETs to alkylating agents needs to be investigated
further before changing clinical practice.
For non-pancreatic NETs, there are two randomised trials. The
ﬁrst compared 5-FU/STZ versus DOX in 172 patients and, using
clinical, biochemical and radiological criteria, reported respective
response rates of 22% and 21%, with no signiﬁcant difference in
survival.
301 The second trial compared 5-FU/DOX versus 5-FU/
STZ in 176 patients and reported a response rate (WHO criteria)
of 16% in both arms, but a superior survival of 24 months for
5-FU/STZ compared with 16 months for 5-FU/DOX
(p¼0.027).
300 Small, single-arm, single-agent studies exploring
newer cytotoxic agents including the taxanes,
313 gemcitabine,
314
pemetrexed
315 and topotecan
316 have not been encouraging,
with response rates of <10%.
Tumour grade (WHO criteria based on Ki-67 and mitotic
index) and differentiation status also inﬂuence response to
chemotherapy. A recent analysis of 82 patients treated with
FCiSt demonstrated responses ranging from 14% for low-grade
tumours to 33% for intermediate-grade tumours, and 60% for
high-grade tumours (p¼0.025). Both Ki-67 (p¼0.019) and
mitotic index (p¼0.008) correlated independently with
response.
308 For Ki-67, a minimum cut-off of 10% was associated
with a response rate of over 38%, but further studies are required
to deﬁne the optimum value to direct therapy. For poorly
differentiated carcinomas, response rates of 42e67%, lasting
a median of 8e9 months, are reported in historical studies using
cisplatin and etoposide.
317e319 Increasing the intensity of treat-
ment by adding paclitaxel to carboplatin and etoposide,
although feasible, had no obvious advantage over doublet
therapy.
320
Given the paucity of adequately powered deﬁnitive phase III
studies incorporating modern response assessments and up-
to-date histological subtyping aimed at reducing patient
heterogeneity, patients and clinicians should be encouraged to
participate in well-designed, prospective clinical trials of
chemotherapy or novel targeted therapies. See under Emerging
therapies below for a discussion of newer agents.
At the time of writing, the use of chemotherapy should be
based on the following principles:
< Where appropriate, patients should be invited to participate
in clinical trials (eg, chemotherapy or novel targeted therapy
trialsdsee under Emerging therapies below).
< For poorly differentiated NETs, a platinum-based regimen
should be considered.
Level of evidence 2, Grade of recommendation B.
< A STZ-based combination should be considered for moder-
ately and well-differentiated tumours, particularly when the
following apply:
– The tumour is pancreatic in origin.
– The tumour is of intermediate or high grade, based on
mitotic index or Ki-67.
– There is rapid clinical or radiological progression.
Level of evidence 1, Grade of recommendation A.
Although there are limited data in terms of efﬁcacy, systemic
chemotherapy could also be considered in patients with recur-
rent and/or metastatic goblet cell appendiceal NETs. The
optimal regimen needs to be deﬁned; however, colorectal cancer
regimens have been used in view of the aggressive nature of this
tumour.
Ablation therapies
Radiofrequency ablation: image-guided ablation
Radiofrequency ablation has been used with some effect in
stabilising or reducing tumour size, but randomised trials are
lacking.
321 It may be indicated in patients with inoperable
bilobar metastases.
322 Ablation therapies are rapidly evolving.
Treatment by ablation can be performed percutaneously or
laparoscopically. Most devices are now able to deliver 3e5c m
spherical ablation zones, and large expandable probes and
multipolar devices can yield larger treatments. The percutaneous
approach is the most commonly used, as it is least invasive,
cheapest and has the additional beneﬁt of CTor MRI guidance.
The laparoscopic approach has the beneﬁt of intraoperative
ultrasound scanning, which is ideal for the detection of tiny
tumours, but it does require considerable skill.
323
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reduce tumour burden. Most patients with neuroendocrine
metastases have a large number of small metastases that are
hormonally active. Parallels should not be drawn with the
ablation experience seen in metastatic colorectal disease. The
Cleveland Clinic group assessed ablation outcomes following
laparoscopic radiofrequency ablation, noting a 34% local recur-
rence rate for colorectal metastases, but only 6% recurrence for
neuroendocrine metastases.
324
The Essen group has usefully stratiﬁed metastatic NETs into
three groups: (1) solitary or paucilesional disease; (2) isolated
metastatic bulk with smaller deposits (often contralobar); and
(3) disseminated metastatic spread.
325 Ablation is usually most
appropriate in groups 1 or 2 alongside resection or as an adjunct
to somatostatin analogue radionuclide therapy. As with surgical
resection or embolisation in the setting of a functioning NET
(usually metastatic midgut NETs), the procedure should be
carried out in conjunction with a prophylactic continuous
octreotide infusion (see under Surgery above).
The main limitation for radiofrequency ablation is the size
and number of tumours. Neuroendocrine metastases are small,
numerous and very slow growing. Therefore, it is possible to
treat patients with indolent disease, with as many as 20 small
(<3 cm) tumours, at multiple treatment sessions over a period
of years. Complete ablation is, however, still limited to small
volume (<4 cm) tumours.
Destroying the largest lesion may not necessarily switch off
hormone production. To achieve a reduction in hormone secre-
tion, it is usually necessary to ablate at least 90% of the visible
tumour.
326e331 Tumour location is not as important as for liver
resection. Recent case series suggest that after laparoscopic
radiofrequency ablation for NET liver metastases, local recur-
rence is around 6% and symptomatic relief is achieved in
70e95% of patients, with a 5-year survival of 57% and a median
survival of 3.9 years after the ﬁrst radiofrequency ablation.
324 332
Patients who have biliaryeenteric anastomoses after pancreatic
surgery are at signiﬁcant risk of secondary infection in
the ablated area of the liver and require 3 months of rotating
oral antibiotics after the procedure. All cases considered for
cytoreductive ablation should be discussed at a specialist
hepatobiliary MDT meeting.
Targeted radionuclide therapy
Systemic targeted radionuclide therapy
This is a useful approach for patients with inoperable or
symptomatic NETs and has become a standard of care for these
patients in the UK and Europe. Signiﬁcant responses have been
observed in patients who would otherwise not be treatable.
Indications for treatment include symptom palliation after
maximal medical therapy and tumour progression. Patient
selection criteria include demonstration of superior radiophar-
maceutical uptake at all known tumour sites on diagnostic
imaging by comparison with normal tissues, reasonable bone
marrow reserve, and adequate renal function. Contraindications
include pregnancy and breast feeding. Patients should be conti-
nent and self-caring in order to minimise risk to nursing staff.
Several different therapeutic radiopharmaceuticals are available.
No randomised controlled trials have been performed.
131I-mIBG
Up to 80% of functioning malignant NETs concentrate mIBG,
333
although the intensity of tumour uptake by comparison with
normal tissues is often too low to justify high-activity radio-
nuclide therapy. Treatment protocols vary between different
centres.
131I-mIBG therapy is administered in a dedicated,
shielded isolation facility for radiation protection reasons.
Thyroidal uptake of free radioiodide is prevented by potassium
iodide/iodate blockade.
The usual prescribed
131I-mIBG activities in the UK range
between 7.4 and 11.2 GBq administered at 3e6-month intervals.
mIBG therapy is the only licensed radionuclide therapy for
NETs. Treatment is well tolerated, and toxicity limited to
temporary myelosuppression 4e6 weeks after therapy. Myelo-
toxicity is more severe in patients who have bone marrow
inﬁltration by tumour at the time of treatment or who have
undergone previous chemotherapy or radionuclide therapy.
Myelosuppression is cumulative and may be dose-limiting after
repeated treatment cycles.
Response rates of 40e60% have been reported after repeated
cycles of
131I-mIBG therapy.
334e336 Treatment offers symptom
palliation, improved QoL and reduced requirements for
somatostatin analogue therapy. Partial objective responses (by
the WHO criteria) of 10e15% have been reported,
335 but
complete radiological response is rare. Survival beneﬁt appears to
be related to symptom response and initial administered activity,
with a reported actuarial survival improvement of 22% at
5 years.
335 Hormone response is not associated with survival
gain.
Radiolabelled peptide therapy
Experience using different radiolabelled peptides has been
published but no randomised controlled comparison between
individual radiopharmaceuticals has been undertaken. The
radiolabels of choice are Yttrium-90 (
90Y) and Lutetium-177
(
177Lu). Available peptides include DOTATOC, DOTATATE,
DOTA-lanreotide and DOTANOC, which exhibit different
afﬁnities for individual SSTR populations. Optimal peptide
selection in an individual patient is determined by diagnostic
tracer imaging. The main toxicities of radiopeptide treatment
are temporary myelosuppression and radiation nephritis. Nausea
and vomiting during and immediately after treatment are partly
attributed to co-administration of amino acids for renal
protection (see below) and are mitigated by prophylactic anti-
emetics. Pain due to temporary radiation oedema may occur in
patients with bulky tumours and is managed by corticosteroids
and analgesics.
90Y-DOTATOC and 90YDOTATATE
Activities in the range 3e6 GBq administered at 6e8-week
intervals, to a cumulative activity of 12e18 GBq, are recom-
mended. Most patients report subjective beneﬁt within two
treatment cycles, often in association with a reduction in
biochemical tumour markers.
A phase II single-arm study
337 of 90 patients with refractory
NETs treated with three cycles of
90Y-edotreotide reported
a response rate of 74.4% (objective response + stable disease),
and prolonged overall survival compared with historical controls
(26.9 vs 12months).
338 Objective response (>50% partial and
complete response) in the range 9e33% by the WHO/RECIST
criteria has been reported with
90Y-DOTATOC,
339 340 with
a median time to progression of 29 months and overall survival
of 36.7 months from treatment. A study of
90Y-DOTATATE in
patients with progressive disease reported partial responses in
23% of patients, with the remaining 77% having stable
disease.
341
Toxicity is actively related and includes reversible myelosup-
pression, which is maximal at 4e6 weeks after treatment,
and nephrotoxicity.
340 Co-administration of amino acids,
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essential to minimise renal toxicity. Patients with pre-existing
microangiopathy due to hypertension or diabetes are at
increased risk of cumulative nephrotoxicity, which may lead to
a decrease in creatine clearance of 7.9% per annum.
340
177Lu-DOTATATE
Responses to cumulative activities of 22e29.6 GBq administered
in 3.7e7.4 GBq fractions at 6e10-week intervals have been
reported: rates of 28% partial response and 54% minor response/
stable disease were recorded in a population of patients with
refractory, progressive disease at the time of treatment.
342
Predictive factors for favourable objective response included high
selective tumour uptake on pretreatment imaging and limited
hepatic metastatic tumour burden.
339 Haematological toxicity is
similar to that reported for
90Y-DOTATOC,
341 although the risk
of nephrotoxicity in a small, unrandomised study was report-
edly lower, with a decrease in creatinine clearance of 3.8% per
annum. Symptom palliation and QoL improvement as assessed
by EORTC QLQ-30 have been demonstrated, although not in
a randomised trial.
342
Future developments
The therapeutic potential of peptides radiolabelled with
a particle emitters
343 and combination treatment with radio-
sensitisers
344 is being investigated in preclinical studies. On the
basis of emitted b particle range, long-range
90Y may be more
suitable for treating bulky metastases, whereas
177Lu would be
preferable for small volume disease. Combined
90Y and
177Lu
radiolabelled therapy is under consideration. Access to some
form of radionuclide therapy should be made available to centres
treating patients with NET.
Transhepatic artery embolisation/chemoembolisation
Particle embolisation (polyvinyl alcohol and gel foam powder) of
the hepatic artery in patients with liver metastatic NETs has
been shown to reduce tumour size and hormone output. It is
primarily used for palliation of symptoms.
345e348 Chemo-
embolisation is the regional delivery of chemotherapy (DOX,
STZ or cisplatin) in combination with hepatic artery embolisa-
tion. The beneﬁts of chemoembolisation have been documented
by several investigators,
349e351 but there are no completed
comparative studies between the two modalities.
There have been several studies since the last guidelines
2
looking at outcomes from embolisation and chemo-
embolisation.
204 352e358 The predominant beneﬁt of the proce-
dure is palliation of symptoms, with 70e90% of patients
achieving beneﬁt. There may be an additional beneﬁt of radio-
graphic regression of metastasis with a possible improvement in
survival, although this has not been demonstrated in a system-
atic study. Five-year post-embolisation survival rates of 28e44%
for NET liver metastases and 18e35% for islet cell metastases
have been documented. PFS of 8e22 months and 16 months for
NETs and islet cell liver metastasis, respectively, has also been
reported. Serious adverse events (sepsis, hepatorenal syndrome
and necrotising cholecystitis) have been reported in 7.5e23.8%
of patients. Post-embolisation syndrome (fever, abdominal pain
and nausea) is common and usually lasts for 24e72 h.
The 30-day mortality from published data is 1.9e9.3%.
However, recently the technique of selective hepatic embolisa-
tion has developed, whereby the left or right hepatic arterial
branches arising from the main hepatic artery are embolised
separately. This is thought to reduce the risk of morbidity
and mortality. Patient selection is the key to reduce major
complications. Patients with >75% liver involvement with or
without liver insufﬁciency, portal vein thrombosis and signiﬁ-
cant carcinoid heart disease are at increased risk of mortality
from the procedure. Other considerations include the presence of
systemic infections, signiﬁcant renal impairment and biliary
reconstructive surgery/obstruction. We recommend a multistage
technique, aggressive hydration and octreotide infusion (50 mg/
h), starting 12 h before the procedure and continued until 48 h
after. Intravenous hydrocortisone, prophylactic antibiotics and
allopurinol for tumour lysis syndrome may also be considered.
On the basis of published data, there seems no signiﬁcant
advantage of chemoembolisation over embolisation. However,
given the better response of islet cell cancers to chemotherapy,
these tumours may have a better response to chemoembolisation.
Selective internal radiation microsphere therapy
Embolisation of the hepatic artery with
90Y microspheres for
unresectable neuroendocrine liver metastases was ﬁrst described
in 1968.
359 360 Three recent studies have investigated the beneﬁts
of
90Y radioembolisation.
360e362 Early data indicate that it is
safe, with no observed deaths within 30 days of treatment in
148 patients. Post-embolisation syndrome was common, and
there was a small risk of radiation gastritis and ulceration.
Embolisation of the gastroduodenal artery before the procedure
may be considered to avoid this. The symptomatic response rate
was 55% at 3 months and 50% at 6 months; 2.7% of procedures
resulted in complete response, with 60% showing a partial
response. Median survival was 70 months.
361 Further long-term
studies are needed to clarify the role of
90Y microsphere embo-
lisation in the management of patients with unresectable NET
liver metastases.
External-beam radiotherapy
NETs have often been regarded as being radioresistant. However,
external-beam radiotherapy may provide excellent relief of the
pain from bone secondaries, and there has been a suggestion that
some secondary deposits in the liver and elsewhere shrink in
response to radiotherapy. It is also useful for the occasional
patients with brain metastases.
363
Emerging therapies
Current systemic anticancer agents (conventional cytotoxics)
have limited efﬁcacy in metastatic NETs. Although results are
somewhat better for poorly differentiated carcinomas and
pancreatic primaries than for other sites, response rates are low
and the impact on survival is small. The greatest unmet need in
the management of NETs is for new agents and approaches to
therapy to improve outcomes. An increasing understanding of
the biology of these tumours, together with the ability to
synthesise drugs that can interfere with relevant targets,
provides an opportunity for the discovery of new therapies.
A major recent development has been the emergence of two
new treatment options (sunitinib and everolimus) for patients
with advanced (inoperable locally advanced or metastatic),
progressive (deﬁned as evidence of radiological disease progres-
sion within the previous 12 months by RECIST), well-differen-
tiated pancreatic NETs.
364 365
The ﬁrst of these, sunitinib malate (Sutent; Pﬁzer), is an oral
inhibitor of the tyrosine kinases downstream from key drivers of
tumour angiogenesis, including vascular endothelial growth
factor (VEGF) types 2 and 3, platelet-derived growth factor and
stem-cell factor (c-kit). Pancreatic NETs are highly vascular
tumours that have increased VEGF expression; xenograft models
treated with VEGF antibodies show signiﬁcant growth
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Guidelinesinhibition and reduction of liver metastases. High VEGF
expression in tumour biopsy samples correlates with metastatic
potential and poorer survival.
On the basis of encouraging results from a phase II study,
366
a phase III double-blind study of sunitinib 37.5 mg per day
(continuous daily dosing) or placebo was conducted in patients
with well-differentiated, progressive pancreatic NETs. The study
was closed prematurely (after enrolment of 171 of the planned
340 patients) by the Independent Safety Monitoring Committee
following an observed increase in the number of adverse events
and deaths in patients receiving placebo. The primary end point
(PFS) was statistically superior for patients receiving sunitinib
compared with placebo (median 11.4 months vs 5.5 months;
p¼0.0001), with a HR of 0.42 (95% CI 0.26 to 0.66; p<0.001).
The objective response rate was 9.3% for sunitinib, with an
additional 63% of patients having stable disease (radiologically,
by RECIST); in comparison, 60% of patients receiving placebo
had stable disease and none had a response (p¼0.007). Toxicities
were as expected from the use of sunitinib in other tumour
types: the most common major (grade 3e4) toxicities included
neutropenia (12% of patients) and hypertension (10% of
patients). Other notable toxicities (usually grade 1e2) included
diarrhoea, nausea, fatigue, vomiting, hand/foot skin reaction
and, rarely, thyroid dysfunction.
364
The mTOR is particularly interesting as a potential thera-
peutic target because genetic abnormalities in the mTOR
pathway may be critical to the development of some NETs. A
phase II study of the mTOR inhibitor RAD001 (everolimus
(Aﬁnitor); Novartis Pharmaceuticals) in 160 heavily pretreated
patients with pancreatic NETs revealed an overall response rate
of 9.6%, with a further 67.8% of patients experiencing stable
disease.
367 The subsequent phase III study has conﬁrmed this
activity in patients with well or moderately differentiated,
progressive pancreatic NETs. Four hundred and ten patients
were randomised to everolimus 10 mg once daily (continuous
dosing) or placebo. Once again, the study demonstrated
a signiﬁcantly better PFS (the primary end point) of 11.0 months
for everolimus and 4.6 months for placebo (HR 0.35 (95% CI
0.27 to 0.45); p<0.001). Treatment was well tolerated, with
most toxicities of grade 1e2 severity (stomatitis, rash, diarrhoea,
fatigue and infections). More severe toxicities (grade 3e4)
included anaemia (6% of patients) and hyperglycaemia (5% of
patients). Stable disease (by RECIST) was evident in 73% of
patients receiving everolimus, compared with 51% in the
placebo group.
365
The emergence of sunitinib and everolimus as new treatment
options for patients with advanced pancreatic NETs raises
a number of additional questions, including the sequencing with
other treatment options, activity in higher grade (ie, poorly
differentiated) disease, combination with other therapy modal-
ities, activity in non-pancreatic NETs, and use in the different
stages of the disease (eg, in the adjuvant setting). Recommen-
dations cannot be made for any of these with the data currently
available and these questions remain a focus for ongoing and
future research.
Similarly, the effects of targeting other cell signalling path-
ways (eg, insulin-like growth factor and its receptors, and the
epidermal growth factor receptor among others) are subject to
ongoing studies. There are many advantages to exploring the
potential value of new agents in patients with NETs. Patients are
generally ﬁt, despite having extensive disease, and usually have
good organ function preservation. Compared with other
disseminated malignancies, patients with NETs have a relatively
long median survival, which gives new agents a chance to
demonstrate their effect. It is clearly essential to include NET
patients in programmes of phase I and II trials of new agents, as
only in this way will new therapeutic approaches emerge to
produce improved outcomes in the future. The networks that
now exist for the management of these patients provide large
patient numbers and high-quality centres that can undertake
early phase trials.
CARCINOID HEART DISEASE
The development of CHD leads to dramatic worsening of
prognosis in patients with NETs. The 3-year survival of patients
with carcinoid syndrome and CHD was found to be 31%
compared with 68% in patients with carcinoid syndrome
without CHD.
368
The reported prevalence of CHD in patients with carcinoid
syndrome has decreased in recent decades, from 50% to 70%
368 369
to about 20%,
36 probably as a result of the introduction of
somatostatin analogues and other therapies designed to reduce the
tumour load and the production of tumour secretory products.
Up to 20% of patients with carcinoid syndrome present with
CHD at diagnosis.
369 The most common pathology in CHD is
involvement of right-sided valves (tricuspid valve affected more
often than pulmonary). Left-sided lesions occur in up to 15% of
patients with the carcinoid syndrome, but in 47% of patients
with CHD.
36 368 370 Almost invariably in patients with
involvement of left-sided valves, patency of the foramen ovale is
involved.
36 Left-sided CHD is very rarely due to a broncho-
pulmonary NET
371 or very severe, poorly controlled carcinoid
syndrome.
Clinical examination
Auscultatory and clinical examination is not an accurate
predictor of the presence of tricuspid regurgitation.
372 Murmurs
may be difﬁcult to detect because velocities in the right heart are
low. Peripheral oedema, ascites and pulsatile hepatomegaly
develop as the disease progresses.
Biomarkers
Urinary 5-HIAA levels have a high sensitivity (100%) but low
speciﬁcity for CHD and are not suitable as diagnostic biomarkers
for this condition. Natriuretic peptides are neurohormones
released by the atria and ventricles in response to an increase in
wall stress due to both volume and pressure overload.
373 NT-
proBNP seems to be a very useful biomarker of CHD (cut-off
level of 260 pg/ml (30.68 pmol/l)) and could be used to rule out
CHD morbidity in patients with carcinoid syndrome.
374 375
Electrocardiography
The ECG changes in patients with CHD are non-speciﬁc,
376 377
but the ECG is very important for detecting arrhythmias.
Echocardiography
Echocardiography is the mainstay tool for diagnosis of CHD.
36
The features of CHD are well described
368 378 and are patho-
gnomonic in the absence of exposure to the appetite suppres-
sants fenﬂuramine and phentermine, ergot-derived dopamine
agonists, and ergot alkaloid agents such as methysergide and
ergotamine.
377 379 380 Patients develop thickening and reduction
of the mobility and retraction of the leaﬂets/cusps of cardiac
valves. The subvalvular apparatus also becomes involved.
Functionally, a combination of valvular regurgitation and
stenosis occurs, and the right heart chambers become enlarged.
The development of left-sided lesions may be expected in up to
half of patients with CHD.
36
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GuidelinesFigure 1 Algorithm for the investigation of neuroendocrine tumours (NETs). ACP, Acid Phosphatase; BNP, brain natriuretic peptide; CgA,
chromogranin A; EUS, endoscopic ultrasound; FDG, ﬂuorodeoxyglucose; GI, gastrointestinal; GPCA, gastric parietal cell autoantibody; HCG, human
chorionic gonadotrophin; 5HIAA, 5-hydroxyindoleacetic acid; 5HTP, 5-hydroxytryptophan; Men-1, multiple endocrine neoplasia 1; MIBG, meta
iodobenzylguanidine; NF, neuroﬁbromatosis; PET, positron emission tomography; PP, pancreatic polypeptide; PTH, parathyroid hormone; VHL, Von
Hippel Lindau.
Figure 2 Algorithm for the treatment of neuroendocrine
tumours (NETs). MIBG, meta_iodobenzylguanidine; OLT,
orthotopic liver transplantation; SIRT, selective internal
radiation therapy.
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detect intracardiac shunts and patency of the foramen ovale.
Multiple views of each valve should be obtained for optimal
evaluation of right-sided heart valves.
381 When necessary,
transoesophageal echocardiography (two-dimensional and
three-dimensional) should be used.
382
Three carcinoid score models have been developed for assess-
ment of the severity of CHD
383e385; two of these include right
ventricular as well as valvular parameters.
Cardiac MRI and CT
Cardiac MRI can be useful when evaluating the pulmonary
valve, in providing accurate data of right ventricular
function,
386 387 and for the detection of cardiac metastases.
Management
Intuitively, optimising somatostatin analogue therapy should
reduce circulating vasoactive substances and carcinoid syndrome
and therefore may stabilise CHD. However, to date there is no
evidence to support this effect.
384 Cytotoxic chemotherapy has
been associated with an elevated risk of progressive heart
disease.
384
Medical management of pure right heart failure is limited and
consists of relieving symptoms of right heart failure with
diuretic therapy.
Cardiac surgery
Cardiac surgery offers deﬁnitive therapy for symptoms. Marked
symptomatic improvement of at least one New York Heart
Association class occurs after valve replacement.
383 A median
survival of 6 years compares favourably with medically treated
patients, but perioperative mortality is signiﬁcant.
388e390
ORGANISATION OF CARE
There are many treatment modalities available and most are
very expensive with a poor evidence base. Because of the rarity
of NETs, not all clinicians and local hospitals will have the full
expertise to deal with these patients. It is therefore important
that all NET cases are discussed and managed by an MDT or
a regional cancer network group that includes at least one
recognised member with an interest in NETs. The Department
of Health and National Institute for Health and Clinical Excel-
lence (NICE) have developed a comprehensive package of
national guidance (the Improving Outcomes Guidance) for
different cancers, including rare tumours. The vital role of the
MDT has been emphasised in all NICE guidance. In a Depart-
ment of Health Cancer Plan publication, it was stated that
MDTs led to improved communication between various
specialists and therefore patients were likely to receive better
continuity and coordination of care.
391 Although there is no
speciﬁc guidance for NETs, they are classiﬁed as rare cancers;
guidance for rare cancers should therefore apply.
For patients with a suspected familial syndrome (eg, MEN1),
referral to a genetic centre should be accompanied by appro-
priate counselling for the patient and their relatives. Even those
without a familial syndrome will beneﬁt from psychosocial
support and counselling.
392
The patient should have information available with which to
make rational choices about various treatments. Patients should
not only be informed about healthcare and treatment options,
but also be given the opportunity to be involved in decisions
about their own care at all stages of the cancer journey.
391 393 394
The role of the clinical nurse specialist/practitioner or nurse
consultant in the MDT is very important in directing the
patient through the treatment and decision-making process. It
has been shown that nurses are better than doctors in providing
information about disease and treatment, and at breaking
bad news to patients. Information can also be obtained
through centres that regularly treat these patients and from the
organisations below.
UKINETS is an organisation composed of specialist doctors
and nurses from the UK and Ireland that was set up to discuss
the management of NETs. UKINETS can be contacted via their
website: http://www.ukinets.org. The patient support group
Net Patient Foundation (incorporating ‘Living with Carcinoid’)
is open to membership for patients and can be contacted at
http://www.netpatientfoundation.com.
It has been reported that cancer patients prefer doctor- or
nurse-led support groups to patient-led groups
395; therefore the
link between UKINETS and the NET Patient Foundation should
continue to be strengthened.
ALGORITHMS FOR OVERALL CARE
Algorithms for the investigation and treatment of NETs are
given in ﬁgures 1 and 2.
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